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C1q Subcomponent of complement 1 
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TGF-β Transforming growth factor beta 
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TNF-α Tumor necrosis factor-alpha 






Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide spectrum 
of clinical and immunological disorders. Prevalence of SLE is higher in females, while males 
have lower survival rates (1). The mostly involved tissues in SLE include skin, joints, 
kidneys, central nervous system, serous membranes and hematological systems while other 
organs can also be affected but with lower frequency. SLE is characterized by presence of a 
bewildering range of antibodies against self antigens. Clinical manifestations of the disease 
are imposed by the tissue damaging impact of circulating autoantibodies and deposition of 
immune complexes.   
4.1 Epidemiology of SLE 
 
Epidemiological data demonstrate marked variations in gender, age and race. According to 
resent studies, the overall age-adjusted prevalence of SLE varies from 20.6 to 78.5 per 
100 000 persons (2,3) and is approximately 2 to 3 times higher in people of African or Asian 
background than in the white population (4). The incidence of the disease has increased 
approximately 3 times during the last 50 years, likely because of better diagnostics of mild 
SLE cases (5,6). The strongest risk factor of lupus is gender. In most studies, more than 90% 
of patients are women. The female-to-male ratio in general is 7:1, while in the childbearing 
years it increases to 11:1 (7). Known as a disease that develops mostly in women of 
reproductive age, in white population SLE however has the highest age-specific incidence 
rates after the age of 40 (8). Published data for Afro-Americans or HispanIC in USA and 






4.2 Etiological factors 
 
Classically, three main factors are considered in the etiology of SLE: genetic, hormones and 
environment. 
Familial clustering, differences in the concordance rate between monozygotic (24-
57%) and dizygotic (2-5%) twins, suggest a genetic basis in lupus (12,13). Currently, more 
than 20 loci of SLE susceptibility genes are known to contribute to risk of the disease, most of 
which are involved in immune complex processing; Toll-like receptor function and type I 
interferon production; and immune signal transduction in lymphocytes (reviewed in  (14,15)). 
However, no single gene polymorphism was identified to cause lupus itself and SLE is 
considered as a genetically complex condition where 2 or more genetic risk factors need to 
occur in an individual to increase risk of the disease (14).  
Predominantly development of SLE in females, implicates an important role of sex 
hormones. Estrogen and prolactin have been shown to have influence on the regulation of 
immune system including alteration of B-cell maturation and selection, proliferation of T-
cells and promotion of a Th1 response (16-18). Several studies demonstrated increased risk of 
SLE in association with menstrual irregularity or with both short and long menstrual cycles 
(19-21). Protective effect of breastfeeding three or more babies compared with none was 
shown in the Carolina Lupus Study (20). Menopausal status, age at menopause and 
postmenopausal hormone therapy were also shown to be risk factors for SLE (20,21).  
Historically, SLE was considered to be a viral disease. However, last decades of 
investigation did not confirm a viral etiology of lupus. The most promising finding is 
serological evidence of Epstein-Barr virus (EBV) infection in SLE patients. In one study 
almost 100% of patients with pediatric SLE were sero-positive to EBV (22). Retrospective 




EBV antibody titer in people who later developed SLE compared to “non-lupus” individuals 
(23).  
Environmental factors which also can likely be etiological for SLE are chemicals. 
Exposure to silica has been associated with increased risk of SLE (24,25). There are several 
reports about hair dye use as a risk factor for lupus (26,27), however this observation was not 
confirmed in a large prospective study (28).  
4.3 Etiopathogenesis of SLE 
 
The pathogenesis of SLE is composed of two pathological processes: i. break of self-tolerance 
that results in production of antibodies to self-antigens and ii. organ-damaging impact of 
circulating autoantibodies and deposition of immune complexes (IC). 
The immune system normally defends our body from pathogens coming with bacteria, 
viruses or parasites. While the innate immune system acts fast, recognizes pathogens and 
responds in a generic non-specific way, the adaptive immune system has the an ability to 
recognize and remember specific pathogens with response getting stronger each time a 
pathogen is encountered. Aggression of immune system against the host organism is 
prevented through the mechanism of immunological tolerance where immature B- and T-cells 
which bind self antigens are eliminated in bone marrow and thymus (central tolerance) or 
mature autoreactive cells which enter the periphery are suppressed by T-regulatory cells and 
become anergic in the absence of co-stimulation by antigen presenting cells (peripheral 
tolerance) (29,30) 
Several B- and T-cell abnormalities were observed in human and murine SLE 
including abnormal B-cell activation and differentiation to memory or plasma cells (31) and  
regulatory dysfunction of T-cells (32). However, defects in B- and T-cells can not explain the 
main phenomena in the pathogenesis of SLE – how self intracellular antigens become 




The central target for autoantibodies in SLE is nucleosomes. Nucleosomal antibodies 
have been shown to be highly specific for patients with SLE (35-37). Break of self tolerance 
to nucleosomes can similarly contribute to development of autoantibodies to dsDNA as well 
(37,38). Nucleosomes are normal products of apoptosis and generated in vivo only by 
endonuclease digestion of chromatin, therefore accelerated apoptosis, or defects in DNA 
fragmentation or impaired clearance of apoptotic cells can provide a potential mechanism for 
breaking self-tolerance and antigen-driven prolonged autoantibody response (39-41).   
4.3.1 Apoptosis in pathogenesis of SLE 
 
General characteristic of apoptosis 
 
Apoptosis is a programmed genetically controlled cell death characterized by condensation of 
chromatin, DNA fragmentation, membrane blebbing and externalization of 
phosphatidylserine (42). It is initiated through the ligation of specific death receptors on the 
cell surface (extrinsic pathway) or from within the cell as response to DNA damage, defective 
cell cycle, hypoxia or other types of cell stress (intrinsic pathway). The initiation of apoptosis 
is followed by a cascade of enzymatic activations (Figure 1) and identifiable morphological 
changes in cells and in nuclei (43). In the last stage, apoptotic bodies, carrying cellular 
components, present “eat-me” signals and are engulfed by macrophages or dendtritic cells 
(44,45). Clearance of intact dying cells prevents secondary necrosis of apoptotic cells and 










Figure 1. Death receptor signaling.   
 
Pathway diagram reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com). Used with permission. 
 
Apoptosis and autoimmunity 
 
In contrast to apoptosis, primary necrosis is characterized by a rapid loss of the integrity of the 
cell membrane and exposure of intracellular components in the extracellular space, followed 
by activation of inflammasome (a large multimeric cytoplasmic protein complex that enables 




maintain their membrane integrity during the early stage of apoptosis, however at a late stage 
membrane integrity may be lost and cells become “secondary necrotic” (50). If apoptotic cells 
enter the stage of secondary necrosis, they start to release intracellular danger signals 
including high-mobility group box 1 (HMGB1) associated with nucleosomes (51,52), 
caspase-cleaved autoantigens (53) and uric acid (54). Immune cells respond to those signals 
with activation of inflammasomes and recruitment of more immune competent cells, 
production of cytokines and the up-regulation of co-stimulatory molecules, which finally 
cause immune system to be “alarmed” and to break tolerance to intracellular self-antigens 
(reviewed in (54,55)) as shown on Figure 2.  
 




Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology 




Apoptosis and SLE 
 
An increase in the apoptosis rate may exceed the local phagocytic clearance capacity. This 
may lead to accumulation of apoptotic cells and their transformation into secondary necrosis. 
Increased apoptotic activity among peripheral blood cells from SLE patients including 
lymphocytes (56), neutrophils (57) and monocytes (58) and its positive correlation with 
autoantibody production and disease activity (57) has been shown by many researches. 
Correlation between SLE activity and the increased level of apoptosis suggests that high 
apoptotic rate may lead to the production of autoantibodies. Induction of apoptosis of 
monocyte/macrophage in vivo by the administration of chlodronate liposomes to lupus-prone 
mice results in increase of anti-nucleosome and anti-dsDNA antibody production and 
worsening lupus nephritis, while injection of chlodranate in non-lupus-prone mice lead to 
development of anti-nucleosome antibodies but not lupus nephritis (59). Induction of 
apoptosis has also been shown to be the initial event in the pathogenesis of pristane-induced 
lupus in mice (60), which also is complicated by development of lupus-like nephritis.  
In a contrast to increased apoptotic activity, reduction of apoptosis also leads to 
induction of autoimmunity. MRL-lpr/lpr mice which have no expression of a functional 
apoptosis-inducing ligand Fas, develop a spontaneous lupus-like syndrome including 
production of anti-dsDNA antibodies, lupus nephritis and skin lesion (61). Insufficient 
elimination of lymphocytes, observed in those mice, demonstrates that autoreactive T cells 
can survive and cause break of immunological tolerance leading to humoral autoimmunity to 
components of chromatin. In human SLE, the Fas-dependent apoptotic pathway was shown to 
be unaffected (62), however in some lupus patients anti-Fas ligand antibodies were found in 
circulation (63). In vitro, they inhibited Fas-mediated apoptosis in cell lines. This indicates the 
possibility of in vivo inhibition of Fas-mediated elimination of autoreactive lymphocytes and 




Apoptotic bodies or microparticles? 
 
It has been shown that not only apoptotic bodies but microparticles (MPs) can also be 
generated during apoptosis. They incorporate nuclear and cytoplasmic components of dying 
cells and can mediate intercellular communication (64). The diameter range of MPs is 0.1-1.0 
μm. They contain RNA (including ribosomal, massager and microRNA) and cleaved DNA 
(65). Nucleic acids are presented both on the surface and inside the particles. MPs are 
proposed to participate in regulation of thrombosis, vascular reactivity, angiogenesis and 
inflammation (reviewed in (66)). Because of RNA and DNA incorporation MPs are suggested 
to act as autoadjuvants during the establishing of central B-cell tolerance (reviewed in (67)). 
Beside apoptosis they can also be generated during cell activation (64). 
The role of microparticles in pathogenesis of SLE is of high interest since they may 
participate in both central tolerance and peripheral activation of B cells (67). Nucleic acids 
located on the surface of microparticles can interact with B-cell receptors triggering their 
activation while translocation of nucleic acids from MPs into B cells will lead to their 
activation through toll-like receptors and non-toll like receptor sensors. In normal individuals 
this would cause central deletion of autoreactive B cells but in SLE patients this will rather 
contribute to promoting survival of autoreactive B cells due to demonstrated defects at 
checkpoints of negative selection of B cells (68,69). In the periphery, interaction of 
autoreactive B cells with MPs might further lead to their differentiation into autoantibody-
producing plasma cells (67). Therewith, MPs have been demonstrated to be a source of 
extracellular DNA and serve as an autoantigen for anti-DNA antibodies (65,70) and increased 






4.3.2 Nucleases in pathogenesis of SLE 
 
In addition to dysregulated apoptosis or microparticles, impaired degradation of DNA during 
cell death is another process that may lead to extracellular chromatin exposure, break of self-
tolerance and appearance of autoantibodies to chromatin components.  
 
General characteristics of nucleases 
 
In cells undergoing apoptosis, chromosomes are condensed and cleaved at internucleosomal 
regions to generate approximately 200-bp DNA ladders. Chromosome fragmentation is a 
complex biochemical mechanism that involves endonucleases with distinct nuclease activities 
and substrate specificities (73). Two classes of apoptotic nucleases participate in programmed 
cell death according to Samejima and Earnshaw (reviewed in (74), Figure 3). Cell-
autonomous nucleases, which cleave the DNA within a cell, and waste-management nucleases, 
which digest chromatin originated from other cells, not from cells where those nucleases were 
produced. Cell-autonomous nucleases have direct access to the nuclei, while waste-
management nucleases are enclosed in lysosomes or secreted into the extracellular space. The 
lysosomal nucleases participate in chromatin degradation during, for example, phagocytosis, 
and in case of insufficient chromatin fragmentation by cell-autonomous nucleases perform the 
final DNA digestion (75). The secreted nucleases exert their function in the blood stream and 
gastrointestinal tract to clean up DNA released from necrotic cells. Some nucleases can 
represent both classes, when secreted waste-management nucleases could under certain 









Figure 3. Cell-autonomous and waste-management nucleases in apoptosis and necrosis. 
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews (74), copyright 
2005.  
There are two apoptotic nucleases clearly identified to degrade DNA within a cell – 
caspase activated deoxyribonuclease (CAD) and endonuclease G (Endo G).  
CAD is the “professional” apoptotic nuclease. In cells it presents itself as inactive, in 
complex with the inhibitor of CAD (ICAD). When apoptotic stimuli activate the caspases, 
caspase 3 cleaves ICAD from the complex and active CAD digests double-stranded DNA at 
positions within internucleosomal linker DNA (77,78). Cleavage by CAD results exclusively 
in double-stranded breaks (79). In cells that are deficient in CAD or have a caspase-resistant 




is the main cell-autonomous nuclease. At the same time, ICAD-deficient mice develop 
normally, lack of apoptotic DNA fragmentation does not lead to induction of autoimmunity in 
those mice  and they still show residual DNA fragmentation (80,81), suggesting the existence 
of other apoptotic nucleases (74,82). 
Endo G is identified as a mitochondrial endonuclease which can induce chromatin 
degradation in cells lacking CAD (82). It translocates to the nucleus after induction of 
apoptosis and proceeds DNA fragmentation (82). Endo G can be activated through caspase-
independent apoptotic pathway (pro-apoptotic factors Bid and Bim) (82), or in order to 
release of cytochrom c and caspase 3 activation – caspase-dependent apoptotic pathway (83). 
It was shown that cleavage by Endo G results in single-stranded breaks between nucleosomes 
and its function is optimized in presence of DNase I (84). Interestingly, expression of Endo G 
via cisplatin-induced kidney injury was lower in DNase I knockout mice than in wild-type 
mice, demonstrating a potential link between those two nucleases (85). Results of studies on 
Endo G knockout mice remain controversial. The first study showed that Endo G-deficient 
mice died prenatally (86), but the second study reported they are viable (87). In any case, 
living mice without Endo G expression in cells did not demonstrate a compromised immune 
system (87).  
DNase II is classified as a waste-management nuclease (74). It is packed in lysosomes 
and plays the main role in engulfment-mediated DNA degradation (88,89). DNase II has been 
shown to be essential for life since degradation of expelled nuclei from erythroid precursor 
cells proceeds by DNase II in bone marrow macrophages (88). DNase II-deficient mice die at 
birth, owing to severe anemia and defects in the diaphragm (88,89). Lack of DNase II 
expression in macrophages leads to accumulation of DNA fragments in those cells and 
hyperproduction of interferon-β (IFN-β) (75). DNase II knockout mice deficient in interferon 




carrying undigested DNA started to produce TNF-α, and at 2-3 month of age mice developed 
polyarthritis resembling rheumatoid arthritis (88). Interestingly, the knockout of CAD gene in 
DNase II-deficient mice increases interferon-β production up to 10-fold (75). Thus lack of 
engulfment-mediated DNA degradation, especially in combination with reduced chromatin 
fragmentation via apoptosis, contributes to abnormal activation of the innate immune system 
(75).  
DNase I is a secreted protein detected in serum, saliva, intestinal juice, urine, seminal 
fluid and lacrymal fluid (90). Primary regarded as an enzyme of gastrointestinal tract that 
digests DNA in food, it has been found to be required in chromatin breakdown during 
apoptosis and necrosis (91-93), and to function as cell-autonomous nuclease in certain 
circumstances (76). Knockout of DNase I gene in mice on SLE-predisposed background leads 
to induction of autoimmunity, appearance of anti-nucleosome antibodies and development of 
nephritis (94). Indeed, DNase I-deficient mice with a “non-autoimmune” background have 
reduced DNA fragmentation in the intestine (95), indicating physiological role of DNase I in 
the death of intestinal cells. The same mice have been shown to be protected against cisplatin-
induced kidney injury (96)  and gamma radiation (95) – two circumstances known to be 
associated with endonuclease-mediated DNA fragmentation damage.      
There are three other nucleases that were reported to have 39-46% identity to DNase I 
– DNase I-like 1 (DNase IL1), DNase IL2 and DNase IL3. They can function as cell-
autonomous nucleases and participate in chromatin degradation during apoptosis (97-99). 
General characteristics of the nucleases mentioned here are summarized in Table 2.  
DNA degradation is an essential process for life and development. Therefore it is a 
well protected mechanism with complex nuclease interactions. Several cell-autonomous 
enzymes can cleave apoptotic chromatin, while the final digestion proceeds in lysosomes of 




extracellular space and body fluids, however it can also function as cell-autonomous nuclease  
(reviewed in (74)).  
 
Table 2. Properties of the main apoptotic nucleases.   
Nucleases  Cofactor pH 
optimum 
Inhibitor TUNEL* Location Secreted Ref. 
CAD Mg2+ Neutral  Zn2+ + Nuclei, 
cytoplasm 
Not (78) 
EndoG Mg2+, Mn2+ Neutral  Zn2+ + Mitochondria Not (84) 
DNase Il1 Ca2+, Mg2+, 
Mn2+, Co2+ 
Neutral  G-actin, 
Ni2+, Zn2+ 
+ Cytoplasm Not (98,100) 
DNase Il2 Ca2+, Mg2+, 
Mn2+, Co2+ 
Acidic  Zn2+ + Cytoplasm Yes (100) 
DNase Il3 Ca2+, Mg2+, 
Mn2+, Co2+ 
Neutral  Ni2+, Zn2+ + Nuclei Yes  (100-102) 
DNase I  Ca2+, Mg2+, 
Mn2+, Co2+ 
Neutral  G-actin, 
Ni2+, Zn2+ 
+ Cytoplasm Yes  (93,100) 
DNase II None Acidic  - - Lysosomes Not  (103) 
* the ”+” indicates that the nuclease generates 5’-P and 3’-OH ends that can be detected by TUNEL 
reaction.   
 
Nucleases and SLE 
 
Only one nuclease has been shown to be involved in the pathogenesis of SLE so far. Reduced 
serum DNase I activity has been reported in lupus patients (104-107) and lupus-prone 
(NZBxNZW)F1 mice (108,109) and was proposed to cause accumulation of undigested DNA 
and induce production of autoantibodies against chromatin components (104). Therefore, a 
study with administration of DNase I in lupus-prone mice that develop nephritis was 
performed by Macanovic et al. (110). Published data suggested positive therapeutic effect of 
DNase I since progression and severity of the disease were decreased in mice injected 
intraperitoneally with murine DNase I (110). However those results were not reproduced in 
larger study on lupus-prone mice (111) and intravenous and subcutaneous administration of 




disease activity (112). Moreover in an experimental mouse model with pristane-induced 
lupus, mice deficient in CAD did not produce antinuclear antibody (113). Thus, animals 
lacking chromatin fragmentation are impaired in ability to produce antibodies against nuclear 
components. Therewith, knockout of the DNase I gene in mice with “non-autoimmune” 
background did not lead to induction of autoantibodies (96). Taken together those data 
suggest that lacking or reduced chromatin fragmentation per se does not contribute to break of 
immunological tolerance to components of chromatin.  
4.3.3 Impaired clearance of apoptotic cells in pathogenesis of SLE  
 
Increased amount of apoptotic, secondary necrotic chromatin as a main antigen in SLE can 
also occur in the case of impaired clearance of apoptotic cells. Normally, cells undergoing 
apoptosis are removed immediately by non-inflammatory phagocytosis (114). The fast, 
efficient and silent removal of apoptotic cells protects them from transformation into 
secondary necrotsis. If clearance is reduced, apoptotic cells reach a stage of secondary 
necrosis, expose danger signals (including HMGB1, heat shock proteins and uric acid) and 
trigger inflammation (reviewed in (55), Figure 2). Detection of nuclear remnants from 
apoptotic cells in germinal centers in association with the surfaces of follicular dendritic cells 
in SLE patients can explain the mechanism of termination of immunological tolerance to 
chromatin components in SLE (115). Several studies demonstrated functional defects in 
clearance of apoptotic cells in human and murine SLE (115-117). Mice deficient in C1q (C1q 
mediates immune complex and apoptotic cell opsonisation and phagocytosis) and MFG-E8 
(MFG-E8 recognizes and binds apoptotic cells that enhances the engulfment of apoptotic cells 
by macrophages) develop anti-nuclear antibodies and immune-complex mediated lupus-like 
nephritis (118,119). This indicates an important role of effective clearance of apoptotic cells 
as a defensive mechanism to maintain tolerance for e.g. chromatin autoimmunity. Only C1q 




genetic defects causing impaired clearance of apoptotic cells in SLE patients remain 
unknown.       
Thus, several pathological processes can contribute to termination of tolerance to self 
chromatin components in SLE and induce production of anti-dsDNA/anti-nucleosome 
antibodies. Interaction between the autoantibodies and antigens leads to formation of immune 
complexes (IC) that deposit in organs, trigger cascades of inflammation causing tissue injury 
and manifestation of clinical symptoms of the disease. Deposition of IC in patients with SLE 
has been identified in several sites including glomeruli, blood vessels and skin. IC presence 
may be explained by the deposition of circulating IC or by local formation of autoantibody-
antigen complexes in case when target antigen is present within the site. Circulating IC can 
effectively and quickly be cleared by the reticulo-endothelial system in liver and spleen (122-
124). Several studies have reported abnormal processing of IC in SLE patients (125-127) 
including reduced splenic uptake. This may likely be due to complement deficiency (125-
127). But at the same time uptake of IC by liver was found to be increased (125) and final 
clearance of IC was faster in lupus patients (127). On another side, several constitutively 
expressed components of glomeruli have been shown to be recognized by anti-chromatin 
antibodies (including laminin (128,129) and α-actinin (130,131)) while two main components 
of GBM - collagen IV and heparan sulphate, could serve nucleosome-mediated binding of 
anti-nuclear antibodies to glomerular membrane (reviewed in (132,133)). However, there is 
no international consensus about the mechanism of IC deposition in SLE and future 
investigations are required. Nevertheless autoantibodies can by themselves cause cell damage 
by Fc receptor mediated inflammation (134) and/or by direct cytotoxicity. Some 
hematological disorders in SLE as hemolytic anemia and thrombocytopenia are most caused 




4.4 Classification and diagnosis of SLE 
 
Since most organs can be affected by the disease, SLE often presents a diagnostic challenge. 
The main serological marker of SLE is presence of antinuclear antibodies including 
antibodies against dsDNA and nucleosomes. They are present in approximately 80% of lupus 
patients and correlate with disease activity (137,138). Prognosis of SLE is based on disease 
severity and known to be the most unfavorable in case of kidney and nervous system 
involvement. American College of Rheumatology (ACR) developed classification criteria for 
lupus, consisting of the most common clinical and laboratory manifestations, to classify SLE 
for clinical studies. Those criteria however are also provisionally used for the disease 
diagnosis. The 11 ACR criteria for SLE are presented in Table 1. Combination of 4 or more of 
them simultaneously or accumulated over time permits to classify lupus with 96% specificity 
and sensitivity between other autoimmune illnesses (139); nonetheless those criteria were 
never tested on non-autoimmune diseases (140). 
Table 1. Criteria for classification of Systemic Lupus Erythematosus (SLE) modified from 
Tan E.M. et al. (139).  
Criterion  Definition  
1.   Malar rash  Fixed erythema, flat or raised, over the malar eminences 
2.   Discoid rash  Erythematous circular raised patches with adherent keratotic scaling and follicular 
plugging; atrophic scaring may occur 
3.   Photosensitivity Exposure to ultraviolet light causes rash 
4.   Oral ulcers Includes oral and nasopharyngeal ulcers, observed by physician 
5.   Arthritis  Nonerosive arthritis of two or more peripheral joints, with tenderness, swelling or effusion 
6.   Serositis Pleuritis or pericarditis documented by ECG or rub or evidence of effusion 
7.   Renal disorder Proteinuria >0.5 g/d or +3, or cellular casts 
8.   Neurologic disorder Seizures or psychosis without other causes 
9.   Hematologic disorder Hemolytic anemia or leukopenia (<4000/mm3) or lymphopenia (<1500/mm3) or 
thrombocytopenia (<100000/mm3)  in the absence of offending drugs  
10. Immunologic disorder Anti-dsDNA, anti-Sm, and/or anti-phospholipid antibody 
11. Antinuclear antibodies An abnormal titer of ANA by immunofluorescence or an equivalent assay at any point in 




4.5 Lupus nephritis    
 
The classical immune-complex mediated complication in SLE is lupus nephritis.  
4.5.1 General characteristics of lupus nephritis 
 
Lupus nephritis is potentially the most severe clinical manifestation of SLE that affects 30-
60% of lupus patients (141,142). Before 1970, 5-year survival rate of SLE patients with lupus 
nephritis was low and reached only 25-40% (143). The situation has changed during the last 
decades and survival rate increased to 80-95% (144) as a result of using broad-spectrum 
immunosuppressive therapy, introduction of dialysis and renal transplantation. Despite 
intervention, the results of integrated therapy are still insufficient since complete remission 
rates of lupus nephritis are around 50% (145) with relapse rates of up to 30% over 2 years 
(146). Therewith the incidence of end-stage renal disease in SLE has tended to increase in US 
especially among African-Americans and HispanIC (147). 
The diagnosis of lupus nephritis also invokes challenges. The initial clinical symptoms 
of the disease are persistent proteinuria and/or appearance of cellular casts in urine, however it 
can manifest from full-blown nephrotic syndrome with fast progression into end-stage renal 
failure. Laboratory findings in urine as well as a monitoring of anti-dsDNA or other 
autoantibodies in serum do not indicate disease severity. The level of circulating 
autoantibodies is associated with overall disease activity but does not correspond to renal 
pathomorphological changes and degree of kidney damage (148). Correct evaluation of lupus 
nephritis therefore has to be performed by examination of renal biopsy. Histopathological 
evidence of inflammation and affection of different glomerular patterns has been shown to 
represent the extent of kidney injury and well predict the risk of development severe renal 
disease (149). At the same time, renal biopsy is an invasive procedure and has considerable 
procedural risk, and it needs to be repeated during disease progression to diagnose the 




therapy (150,151). Investigation of new less-invasive markers of the disease severity is of 
high interest in lupus nephritis. Several candidates were reported to provide sufficient 
prognostic value of the disease but future studies are needed to be performed to conclude their 
significance in practice (152-154). 
4.5.2 Classification of lupus nephritis 
 
There are six classes of lupus nephritis according to classification criteria developed by 
International Society of Nephrology and Renal Pathology Society (ISR/RPS) working group 
(155). The last revised form of classification from 2003 is presented in Table 3. This 
classification is based on light microscopy, immunofluorescent and electron microscopy (EM) 
analyses of renal biopsies and focuses exclusively on glomerular pathology. Histological 
findings in different glomerular patterns (mesangial, epithelial and endothelial) including 
active or chronic inflammation, necrosis, crescents and IC deposition allow to discriminate 
severity of the disease and renal outcome. Thus Class I lupus nephritis (characterized by 
mesangial IC deposits detectable only by EM and/or immunoflourescence) and Class II 
(appearance of mesangial hypercellularity and extended deposition of IC in mesangium) are 
silent disease, therefore usually non-symptomatic and rarely progress to renal failure 
(155,156). Class III lupus nephritis is characterized by segmental endocapillary proliferative 
lesions and immune deposits in subendothelial glomerular pattern that affect less than 50% of 
all glomeruli, whereas in Class IV more than 50% of glomeruli have to be affected (155). 
Clinically, Class III and IV lupus nephritis present with mild or severe proteinuria (including 
nephrotic syndrome) and are associated with rapid progression to end-stage kidney disease 
(156). Lupus nephritis patients with subepithelial immune deposition in glomeruli (Class V) 
have low rate of progression, typically present with nephrotic syndrome and have high risk of 
thromboembolic events (155,157). Class VI lupus nephritis is the final-stage when chronic 




ISR/RPS classification primarilly focuses on glomerular damage. However several 
studies have reported on the importance of tubulointerstitial inflammation (TI) and its 
predictive role for progression to renal failure (158-160). Since TI can occur independently of 
glomerular injury (161) and does not correlate with titers of anti-dsDNA antibodies it may 
indicate different pathogenic mechanisms for glomerular and interstitial tissue damages 
during development of lupus nephritis (160).  
 
Table 3. Abbreviated International Society of Nephrology and Renal Pathology Society 
classification of lupus nephritis (2003), modified from Weening at al. (155). 
Class I Minimal mesangial lupus nephritis 
Class II Mesangial proliferative lupus nephritis  
Class III Focal lupus nephritis (indicate the proportion of glomeruli with active and with sclerotic lesions)  
Class IV Diffuse segmental or global lupus nephritis (indicate the proportion of glomeruli with fibrinoid 
necrosis and cellular crescents) 
Class V Membranous lupus nephritis (may occur in combination with class III or IV in which case both 
will be diagnosed) 
Class VI Advanced sclerosis lupus nephritis 
 
4.5.3 Pathogenesis of lupus nephritis 
 
Since lupus nephritis is an IC-mediated disease (162,163) three main questions have to be 
addressed: i. which autoantibodies are nephritogenic, ii. what is the central renal target 
antigen and iii. where and how are IC formed.    
 A wide spectrum of autoantobodies has been shown to be associated with lupus 
nephritis including anti-C1q, anti-Ro, antiribosomal antibodies, antibodies to laminin, 
fibrinogen and collagen (reviewed in (133,164)). However, the central role in the 
pathogenesis of lupus nephritis has been attributed to anti-dsDNA and anti-nucleosome 
antibodies (132,165-167). A direct nephritogenic role of anti-dsDNA and anti-nucleosome 




and the presence of anti-DNA antibodies in glomerular immune deposits (170,171). 
Concentration of anti-dsDNA antibodies in eluates from glomeruli exceeds their 
concentration in serum (172) and administration of DNA to autoimmune mice with 
circulating anti-dsDNA antibodies accelerates the progression of nephritis (173). In addition 
injection of anti-DNA antibodies to non-immune mice can induce nephritis (174-176). 
However immunization with dsDNA failed to induce anti-dsDNA antibodies with lupus 
specific characteristics, while the positive results came after administration of dsDNA 
complexed with histone-like DNA-binding proteins (177-179). It has been also shown that T 
cells directed against histones or nucleosomes were able to provide help for the production of 
anti-dsDNA antibodies (36,180). Those observations lead to the conclusion that nucleosomes 
are the driving autoantigen in SLE and lupus nephritis.     
 At the same time there exists evidence that nucleosomes are the central renal targets 
for nephritogenic autoantibodies since they are found in electron dense structure (EDS) in 
murine and human lupus nephritis (165,166). However, many researches have demonstrated 
cross-reaction of anti-nucleosomes antibodies with glomerular membrane components such as 
laminin, α-actinin and collagen (128,131,181-184). Ultra structural analysis of glomeruli by 
various electron microscopy techniques did not show presence of those components within 
the EDS (185,186), and the in vivo-bound antibodies were not observed in regular membranes 
or matrices. Again the main SLE enigma – how can intracellular antigen (nucleosome) 
become able to impose an immune response and at the same time serve as an antigen for the 
induced autoantibodies? The possible mechanisms such as disregulation of apoptosis, 
defective DNA degradation by endonucleases and impaired clearance of apoptotic cells are 
discussed in chapter 4.3. With regard to lupus nephritis, abnormal levels of apoptotic activity 
were observed in diseased kidneys. However published results remain controversial. Several 




other reported decreased renal apoptosis (189,190). In all of these studies conclusions are 
based on histological determination of amount of apoptotic cells on kidney sections. While 
investigation of renal apoptotic activity with integrated assessment of apoptotic triggers, 
executioners and effectors and detection of final apoptotic chromatin fragmentation were not 
performed.  
Decreased serum DNase I was found associated with active phase of class III/IV lupus 
nephritis (191) in respect to possible defect in endonuclease mediated DNA degradation. But 
involvement of serum DNase I in the pathogenesis of lupus nephritis remained elusive since 
administration of DNase I to patients with lupus nephritis did not have impact on the disease 
activity (112). Even the origin of serum DNase I is not well established. Just one recent set of 
data suggested liver as an organ secreting DNase I (192). At the same time little is known 
about DNase I expression and regulation in tissue and particularly in kidneys.  
The mechanism by which autoantibodies form immune complexes in glomeruli has 
been discussed over decades, and the international consensus is still absent. In general there 
are two main theories to consider: 1) pre-formed circulating IC are passively trapped into 
glomeruli and 2) autoantibodies bind directly to endogenous renal antigens. The first theory is 
challenged by evidence that circulating IC should be rapidly cleared by the liver and spleen. 
In addition, administration of DNA/anti-DNA complexes to lupus prone mice resulted in 
decreased disease activity by reduction of autoantibody production (193). The second theory 
has many versions of antibody-binding mechanism including cross-reactions with 
constitutively expressed components of glomeruli (discussed above), nucleosome-mediated 
binding (132) and binding to exposed undigested chromatin fragments (194). None of those 
mechanisms have been ultimately proved and still is a matter of debate.  
It is also not excluded that different stages of lupus nephritis relate to different 




40% of them switch one class of lupus nephritis to another during continuous follow-up 
(150,151). Some patients experience progression from the mild mesangial form to full-blown 
membrano-proliferative nephritis, while others remain with a benign mesangial pattern 
throughout life. 
One of described mechanisms of lupus nephritis development suggests that deposited 
IC trigger a cascade of inflammatory events including activation of Fc receptors and 
complement (reviewed in (195)). Those events lead to recruitment of inflammatory cells. 
Infiltrating macrophages can be responsible for increased expression of metalloproteinase 2 
(MMP-2) and MMP-9 (196,197). Alteration in the composition or integrity of glomerular 
membranes possibly caused by increased MMP activities can facilitate subepithelial 
deposition of IC or chromatin fragments (198). However this mechanism is not well 
established and future investigation are required.  
4.5.4 Animal models for the study of lupus nephritis 
 
Studies of lupus nephritis on human tissue samples are limited for practical reasons. These 
include problem with amount of renal biopsy material, timing difficulties to follow all stages 
of lupus nephritis development in one individual and lack of renal histology information at the 
time of initiation of nephritis. Use of animal models helps to solve many of those problems 
but retains additional question about relevance of research in animals to the human 
counterpart of the disease.   
The (NZBxNZW)F1 mouse is known as an animal model that spontaneously develops 
SLE-like disease. They are generated by the F1 crossbreed progeny of New Zealand Black 
(NZB) and New Zealand White mice. (NZBxNZW)F1 mice develop typical lupus nephritis 
including production of anti-dsDNA antibodies, development of IC mediated 
glomerulonephritis and death from end-stage renal failure or cardiovascular disease (199-




relevance of research findings in the animal model is currently tested in our group on human 












5. Aims  
 
 
 To investigate the mechanism of appearance and origin of chromatin fragments in 
glomerular EDS in kidneys of (NZBxNZW)F1 mice. (Paper I and II) 
 
 To characterize the apoptotic rate in kidneys of (NZBxNZW)F1 mice at different 
stages of lupus nephritis. (Paper II) 
 
 To determine the impact of anti-dsDNA antibodies, renal DNase I and MMPs on 
initiation and progression of lupus nephritis. (Paper III) 
 
 To analyze the organ specificity of acquired renal DNase I reduction and its selectivity 
among endonucleases in (NZBxNZW)F1 mice during development of lupus nephritis. 















6. Summary of the papers 
Paper I. 
 
Reduced fragmentation of apoptotic chromatin is associated with nephritis in lupus-
prone (NZBxNZW)F1 mice. 
Electron dense structures (EDS) containing IgG and chromatin fragments are observed in 
glomerular basement membranes (GBM) of human and murine lupus nephritis. However the 
size of chromatin structures found in EDS was never analyzed. Thus demonstration of 
nucleosomal DNA fragments within the kidneys may be consistent with increased production 
of apoptotic DNA or its impaired clearance since nucleosomes are products of apoptosis and 
generated in vivo exclusively by endonuclease-mediated cleavage of DNA. While the absence 
of low molecular DNA, may be due to reduced fragmentation of chromatin in SLE nephritis. 
We performed analyses of DNA isolated from kidneys of female (NZBxNZW)F1 mice at 
different stages of lupus nephritis and did not find nucleosomal DNA fragmentation even in 
proteinuric animals where TUNEL-positive chromatin particles were detected in glomerular 
membrane by co-localization TUNEL immune electron microscopy. Induction of apoptosis 
ex-vivo by camptothecin in isolated kidneys from young, autoantibody negative 
(NZBxNZW)F1 mice and in kidneys from proteinuric mice with severe nephritis 
demonstrated markedly reduced DNA fragmentation in comparison to age- and sex-matched 
controls. Analysis of mRNA level of central renal nucleases CAD, EndoG and DNase I 
demonstrated a dramatic loss of renal DNase I transcription in mice with nephritis, while 
mRNA levels of CAD and EndoG in all groups of lupus-prone mice remained unchanged 
compared to healthy controls. Thus TUNEL-positive chromatin particles deposited in the 
glomerular membranes of nephritic mice are likely large chromatin fragments accumulated in 





Paper II.  
 
Progression of murine lupus nephritis is linked to acquired renal DNase I deficiency and 
not to up-regulated apoptosis.  
Antibodies to dsDNA and nucleosomes are strongly associated with lupus nephritis. 
Accumulation of apoptotic DNA has been suggested as a possible mechanism of nucleosome 
conversion into self-antigens that may initiate autoimmune response and participate in 
glomerular immune complex deposition. Normally, apoptotic cells are rapidly cleared by 
macrophages. In case of increased apoptotic activity the local phagocytic clearance capacity 
may be exceeded and accumulation of apoptotic chromatin fragments may occur for example 
in glomeruli. Therefore we analyzed mRNA level of apoptosis-related genes and presence of 
activated apoptotic factors within kidneys in (NZBxNZW)F1 mice during development of 
lupus nephritis. We did not find changes in apoptotic activity in kidneys at the time of 
appearance of anti-dsDNA antibodies as well as at the time of formation of mesangial 
immune deposits. In contrast, in kidneys with membrano-proliferative lupus nephritis, 
characterized by deposition of large chromatin fragments in glomerular basement membranes, 
we found increased amount of activated caspase 3-positive cells in kidney sections, 
unchanged mRNA levels of the apoptosis-related genes and a dramatic decrease in renal 
DNase I gene expression. Accumulation of activated caspase 3-positive cells was also 
observed in isolated nephritic kidneys where apoptosis was induced ex-vivo by camptothecin 
and lack of apoptotic chromatin fragmentation was observed. Taken together, our data suggest 
that apoptotic activity in kidneys of (NZBxNZW)F1 mice is not accelerated. Down-regulation 
of DNase I leading to accumulation of undigested apoptotic cells may be responsible for the 
transformation of mild mesangial lupus nephritis into severe membrano-proliferative end-







Anti-dsDNA antibodies promote initiation, and acquired loss of renal DNase I promotes 
progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. 
There is an international consensus that appearance of anti-chromatin antibodies is an initial 
event in the pathogenesis of lupus nephritis. The mechanism of the renal disease progression 
is elusive. We demonstrated that EDS in glomeruli of lupus-prone (NZBxNZW)F1 mice 
contain chromatin fragments and that there is a defect in apoptotic DNA fragmentation in 
nephritic kidneys associated with reduced mRNA level of renal DNase I. We have also 
reported that activity of metalloproteinases (MMPs) is increased during progression of 
nephritis in (NZBxNZW)F1 mice. To analyze the factors that contribute to lupus nephritis 
development we performed a study where mRNA levels and activities of DNase I, MMP2 and 
MMP9 were correlated with each other and with anti-dsDNA antibody production, with 
successive deposition of IC in the mesangial matrixes and in glomerular basement membranes 
(GBM), and with progressive proteinuria.   
We observed that lupus nephritis in female (NZBxNZW)F1 mice is principally two-
stepped organ disease. The early phase correlated with deposition of complexes of chromatin 
fragments and IgG in the mesangial matrix. Progression of the disease, which was 
characterized by deposition of large chromatin fragments in GBM and severe proteinuria, 
correlated with an acquired loss of renal DNase I mRNA level and enzyme activity. We 
proposed that loss of DNase I, as a dominant renal nuclease, leads to reduced chromatin 
degradation during regular apoptosis in the kidneys. In case of impaired clearance of 
apoptotic cells, this may explain exposure of chromatin fragments in membranes and matrices 
of affected glomeruli. Increased MMP2 and MMP9 expression, observed in nephritic kidneys, 
may contribute to alterations in the composition or integrity of GBM that facilitate binding of 






Acquired loss of renal nuclease activity is restricted to DNase I and is an organ-selective 
feature in murine lupus nephritis. 
Reduced DNase I was observed in nephritic kidneys of (NZBxNZW)F1 mice at the stage of 
IC deposition in GBM. An acquired loss of renal DNase I has been suggested as a promoter of 
transformation of mild mesangial lupus nephritis into membrano-proliferative end-stage organ 
disease. However, DNase I expression in other organs of (NZBxNZW)F1 mice as well as 
expression profiles of other endonucleases in (NZBxNZW)F1 mice has never been examined. 
Only reduced serum DNase I activity in nephritic animals was reported but its importance in 
kidney pathology during development of lupus nephritis seems unclear. We analyzed mRNA 
level of DNase I, DNase IL1-3, caspase activated deoxyribonuclease (CAD), Dnase2a, and 
endonuclease G (Endo G) in kidneys, spleens and livers isolated from lupus-prone mice at 
different stages of lupus nephritis. DNase I activity and total nuclease activity were measured 
in kidneys, livers, spleens and sera of (NZBxNZW)F1 mice during progressive kidney 
disease. Our results demonstrate no reduction of DNase I mRNA level and enzyme activity in 
liver, spleen and serum samples of (NZBxNZW)F1 mice throughout all stages of lupus 
nephritis. DNase I was dramatically and selectively reduced only in kidneys of mice with 
severe nephritis and was the only nuclease that was down-regulated, while 6 other nucleases 
(Dnase1L1-3, CAD, Dnase2a, and Endo G) in kidneys were normally expressed. Loss of renal 
DNase I was not accompanied by changes in serum DNase I activity, suggesting an 
independent mechanism of the nuclease regulation in circulation and in kidneys and absence 
of compensatory up-regulation of serum DNase I activity in the case of renal DNase I 
deficiency. Thus, silencing of renal DNase I is a unique renal feature in membrano-







7.1 Origin of chromatin fragments in glomerular EDS – accelerated renal 
apoptosis or defect in renal DNA degradation?   
 
Antibodies to dsDNA and nucleosomes are strongly associated with lupus nephritis. 
Nucleosomes were suggested to play a dual role in the pathogenesis of the disease; they may 
initiate an autoimmune response and participate in glomerular immune complex deposition 
(34,132). Electron-dense structures containing TUNEL-positive autoantibody-binding 
chromatin are associated with glomerular capillary membranes and mesangial matrix in 
nephritic lupus-prone (NZBxNZW)F1 mice (165,166,202). Presence of TUNEL-positive 
extracellular chromatin indicates DNA fragments with 5’-P and 3’-OH ends that are generated 
by endonucleases during apoptosis. Accessibility of such fragments for autoantibody binding 
at physiological circumstances is prevented by formation of apoptotic bodies containing 
degraded DNA and their rapid clearance by macrophages. Thus appearance of chromatin 
fragments in EDS and manifestation of lupus nephritis likely occur due to disturbances in 
apoptotic DNA cleavage and/or impaired clearance of apoptotic cells.  
The origin of IC accumulated in glomerular membranes is not clear. They can come 
from circulation and deposit due to filtration through the capillary walls or they can be formed 
locally with glomerular antigens. Studies with administration of pre-formed IC demonstrated 
their deposition mainly in mesangial matrix and subendothelial spaces, but not subepithelially 
(reviewed in (203,204)). In situ deposit formation was shown to occur in all glomerular 
patterns: mesangial, subendothelial and subepithelial (204). Different structures that can serve 
as a renal antigen in lupus nephritis were matter of discussions during the last decades. Cross-
reaction of anti-dsDNA antibodies with inherent glomerular components like laminin (129)  




and proposed as a central mechanism of antibody-binding in glomeruli. However those 
structures were not indentified in EDS by EM analysis (185,186). In respect to presence of 
DNA fragments in EDS and inability of circulating IC to deposit in subepithelial glomerular 
spaces as demonstrated experimentally (204) we proposed that pathological process leading to 
accumulation of chromatin within glomeruli can rather have a renal origin at least at the stage 
of membrano-proliferative nephritis. One simple explanation could be an increase in 
glomerular cell apoptosis as was already reported by different research groups (165,187,188). 
However they based the conclusion only on increased amount of apoptotic cells in kidney 
sections that can also occur due to impaired clearance of apoptotic material by macrophages. 
Moreover some studies demonstrated reduced apoptosis in lupus nephritis (189,190). To 
thoroughly determine the renal apoptotic rate in lupus nephritis we performed an integrated 
assessment of apoptotic triggers, executers and effectors in kidneys of (NZBxNZW)F1 mice 
at different stages of the disease (206). Our results demonstrate no evidence of accelerated 
renal apoptosis before or at the time of anti-dsDNA antibody production as well as at the time 
of clinical manifestation of kidney disease (mesangial nephritis). Only slightly increased 
amount of activated caspase 3-positive cells was found in kidney sections from mice with 
membrano-proliferative lupus nephritis mostly in tubular cells and in the interstitium (206). 
This increase was not accompanied by changes in mRNA level of apoptotic regulators and 
executors. These data suggested that rate of apoptosis in kidneys of (NZBxNZW)F1 mice is 
not increased by activity, and accumulation of extracellular chromatin in glomerular 
membranes at the stage of nephritis most likely occur due to other pathological processes. 
This conclusion was also consistent with our previous observation, that presence of TUNEL-
positive chromatin particles in glomerular membranes in kidneys of (NZBxNZW)F1 mice 
correlated with lack of detection of LMW DNA fragments in DNA isolated from nephritic 




suggest increased ongoing apoptosis and/or impaired clearance of apoptotic cells. Absence of 
low molecular weight DNA in kidneys with TUNEL-positive EDS in glomerular membranes 
could indicate presence of large chromatin fragments that most likely appear due to defects in 
apoptotic chromatin fragmentation.  
We determined LMW DNA in kidneys of (NZBxNZW)F1 mice using the Agilent 
bioanalyzer that is a sensitive electrophoretic assay. Clear LMW DNA ladders were observed 
in isolated BALB/c kidneys exposed to apoptosis inducer camptothecin (CPT), whereas only 
few active caspase 3-positive cells were present. Surprisingly, when we induced apoptosis ex-
vivo by CPT in isolated kidneys from (NZBxNZW)F1 mice we found markedly reduced 
DNA fragmentation compared to age- and sex-matched healthy controls (202). The amount of 
active caspase 3-positive cells observed in those kidneys was significantly higher then in 
controls (206) demonstrating that apoptosis was induced in (NZBxNZW)F1 mice but was not 
completed with final DNA degradation. These results together indicate that TUNEL-positive 
extracellular chromatin particles found in EDS can represent large DNA fragments 
accumulated in glomeruli due defective chromatin fragmentation in kidneys of 
(NZBxNZW)F1 mice. Defects in DNA cleavage may be explained by lack of DNase I since 
dramatically reduced mRNA level of this nuclease was found to be associated with nephritis 
in lupus-prone animals (202,206).  
7.2 Acquired loss of renal DNase I in development of lupus nephritis 
 
DNase I in kidneys has been shown to represent approximately 80% of the total nuclease 
activity and mostly expressed in tubular epithelial cells (96,202). Role of the enzyme is not 
well established but it has been reported that mice deficient in DNase I expression are 
protected from kidney injury mediated by cisplatin (96). This chemotherapeutic drug induces 




up-regulated during kidney injury induced by ischemia-reperfusion in in vivo experiment 
(209). Those data indicate an importance of DNase I to clear death-associated chromatin. 
The mechanism of chromatin fragmentation and breaking down during necrosis by 
serum DNase I was experimentally demonstrated. Results showed that the nuclease can 
penetrate necrotic cell, accumulate in the cytoplasm and nucleus and proceed DNA cleavage 
(92). How DNase I can participate in apoptotic chromatin fragmentation is not clear since this 
is a secreted protein and does not have direct access to the cell nucleus. Data from 
experimental induction of apoptosis in cells deficient to DNase I are also controversial. While 
one paper demonstrate resistance to apoptotic stimuli in cells after disruption of the DNase I 
gene (76), another paper report that no difference in the sensitivity towards the induction of 
apoptosis was observed in tissues and cells from DNase I knockout mice with lupus 
predisposed background  in comparison to wild-type animals (210). On the other side, 
reduced chromatin fragmentation and cell death was found in the intestine of DNase I 
deficient mice with “non-lupus” background (95). In spite of contradicting results, the fact 
that DNase I activity in kidneys is dominant compared to other nucleases and importance of 
DNase I in renal cells death implicates its essential role for DNA digestion during the cell life 
cycle.  
Abnormal levels of DNase I activity was observed in association with a variety of 
diseases. A high serum DNase I was measured in patients with advanced liver diseases (211), 
acute hemorrhagic pancreatitis (212), several cancers (213-215) and renal failure (216), 
whereas low level was found in patients with xeroderma pigmentosum (108).  Involvement of 
DNase I in the pathogenesis of lupus nephritis was discussed back in 1981 when decreased 
serum DNase I activity was observed in lupus patients (107) and later on in lupus-prone mice 
(108). Detection of DNA in circulation together with low DNase I activity in serum could 




autoimmunity to self chromatin in SLE (107). Interest to this idea was cooled down when 
intravenous administration of DNase I to patients with lupus nephritis did not lead to 
suppression of disease activity (112).  
Discovery of a defect in apoptotic DNA fragmentation of ex-vivo camptothecin 
induced apoptosis in kidneys of (NZBxNZW)F1 mice stimulated us to analyze renal 
expression of endonucleases during development of lupus nephritis (202). The mRNA levels 
of CAD, EndoG and DNase I were measured in kidneys of (NZBxNZW)F1 mice at different 
age groups. Dramatic reduction of the transcription level of DNase I was observed when 
mesangial nephritis progressed into end-stage organ disease, whereas CAD and EndoG 
remained unchanged in all groups of animals. To investigate the relevance of DNase I renal 
gene expression to development of lupus nephritis we performed a longitudinal study where 
we analyzed mRNA level and enzyme activity of DNase I in kidneys of (NZBxNZW)F1 mice 
and correlated the data with appearance of circulating anti-dsDNA antibodies, deposition of 
IC in the mesangial matrix and/or glomerular membranes, and with proteinuria (217). Our 
data demonstrate that initiation of lupus nephritis was associated with anti-dsDNA antibody 
production and correlated with appearance of EDS in the mesangial matrix. End-stage 
nephritis on the other hand, was characterized by severe proteinuria and IC deposition in 
GBM and an acquired loss of renal DNase I (217). Based on these results we proposed that 
lupus nephritis in female (NZBxNZW)F1 mice is a two-stepped organ disease with possibly 
two different pathogenetical mechanisms of forming deposition of IC in glomeruli. Initiation 
of lupus nephritis can be due to deposition of IC possibly coming from circulation. It can 
explain the systemic character of tissue damage in SLE. Comparative studies of components 
of IC and their localization in skin and glomeruli demonstrated that they have similar 
structure and are consistently observed in capillary lumina in both skin and kidney (218,219). 




Importantly, deposition of IC in glomeruli did not predict deposition in skin. Examination of 
DNase I and MMP expression in skin in MRL-lpr/lpr mice demonstrated stable low activity 
of DNase I and an increase in MMP-2 and MMP-9 enzyme activities during disease 
progression (219). Those results confirm that circulating IC can be an initial event of SLE 
manifestation in different organs, but mechanism of tissue damage progression might be 
organ restricted. Our data suggest that progression of lupus nephritis is caused by 
accumulation of large chromatin fragments in glomeruli due to insufficient DNA 
fragmentation in kidneys deficient of renal DNase I expression. Access of such fragments in 
GBM can be facilitated by increased MMP activity since increased expression and activities 
of MMP-2 and MMP-9 were observed at the time when severe nephritis developed in 
(NZBxNZW)F1 mice (217).   
7.3 Loss of renal DNase I – a systemic error or an organ-selective feature? 
 
Distribution of the DNase I activity in different tissues and cells has been published for 
humans and other mammals (90,220,221). According to the expression pattern within the gut 
they can be grouped into three types: pancreas type (pig and human), parotid type (rat and 
mouse) and mixed pancreas-parotid type (bovine and rabbits) (221). Difference in DNase I 
expression is most probably reflecting variation in the eating habits (221). Furthermore beside 
the intestinal juice, DNase I is secreted into urine (kidney), seminal fluid (prostate), 
lacrhrymal fluid (lachrymal gland) and serum (90). The origin of serum DNase I is not 
known. Recent data indicated liver as a source of DNase I in serum (192). The dominant 
function of serum DNase I is digestion of chromatin material released in circulation. If serum 
DNase I contribute to intracellular DNA fragmentation has never been shown.  
Reduced serum DNase I activity was demonstrated in human and murine SLE. We 
found lack of DNase I in kidneys at the time of severe lupus nephritis in (NZBxNZW)F1 




specific feature or if it reflects a systemic error in BW mice. In Paper IV we performed analysis 
of DNase I expression and enzyme activity in spleen and liver tissues in comparison to 
pathological changes in kidneys during progressive lupus nephritis. Our data demonstrate that 
loss of renal DNase I is an organ-selective feature in lupus-prone mice with membrano-
proliferative nephritis. Moreover analysis of mRNA levels of 6 other known endonucleases 
(DNase Il1-3, CAD, Dnase2a, and EndoG) demonstrates absence of compensatory up-
regulation in kidneys or livers, neither at the time of mild nephritis nor after it transformation 
into severe disease with renal DNase I deficiency.  
Interestingly we did not observed reduction in serum DNaseI activity in mice with 
full-blown nephritis in contradiction to previously published data (109). Nuclease activity in 
serum of (NZBxNZW)F1 mice with membrano-proliferative nephritis measured by a DNase 
radial diffusion assay and serum DNase I activity measured by denaturing SDS-PAGE 
zymography were comparable to activities detected in pre-nephritic animals. Notably, the 
degree of serum DNase I activity in the different groups of (NZBxNZW)F1 mice correlated 
with DNase I activity in the liver and not in the kidney, in accordance with results provided 
by Ludwig at. al. (192). Those findings refer to the important question - is serum DNase I a 
required pool for the kidneys in the situation were renal DNase I is lost? We do not have data 
to provide an answer to this question. Oppositely, failure of an affect on lupus nephritis after 
DNase I administration in lupus patients (192) or in (NZBxNZW)F1 mice (111) indicates 
low-relevance of serum DNase I in renal environment. This leaves us with the perception that 
renal, intra-cellular DNase I is required for safe degradation and elimination of chromatin 
from dying renal cells. Without this enzyme, chromatin degradation is impaired, which results 





7.4 Clearance deficiencies in lupus nephritis 
 
A large amount of cells undergo apoptosis every day but to detect them in situ is difficult, 
because they are quickly engulfed by macrophages and immature dendritic cells (44). An 
accumulation of apoptotic cells in the bone marrow and in the skin of lupus patients has been 
reported (222,223) as well as decreased clearance of apoptotic cells by macrophages in human 
and murine SLE (115,117,224). The exact mechanism leading to impaired clearance of 
apoptotic cells in lupus is not known. Deficiency in the components of the classical 
complement cascade including C1q, C2 and C4 are associated with high risk of SLE (225). 
Mice deficient in C1q develop lupus-like disease (226). Acquired and transient deficiency of 
C1q commonly found among SLE patients may be due to consumption by large amounts of 
IC or binding to anti-C1q antibodies rather than genetic defect (226).  
Professional phagocytes detect apoptotic cells due to recognition of “eat-me” signals 
on their surfaces (including phosphatidylserine, intercellular adhesion molecule-3, Annexin I 
and cardiolipin) (227-229). Absence of such signals or defects in phagocyte recognition may 
lead to impaired clearance of apoptotic material (119,230). The uptake of apoptotic cells by 
phagocytes induces the expression of “tolerate me” signals including interleukin 10 (IL-10), 
transforming growth factor β (TGF-β) and prostaglandin E2 (PGE2) (55,231). If apoptotic 
cells reach a stage of secondary necrosis due to for example impaired clearance, their uptake 
is followed by production of pro-inflammatory cytokines and up-regulation of co-stimulatory 
molecules. In other words, impaired clearance of apoptotic cells may lead to central 
pathological processes in the pathogenesis of SLE: i. it may break self-tolerance to chromatin 
and ii. it may enable exposure of extracellular chromatin (self antigen) in tissue (reviewed in 
(55,194)).   
Generation of large chromatin fragments due to lack of DNase I likely can be 




contribute to clearance deficiency and accumulation of extracellular DNA in nephritic kidneys 
(reviewed in (232)). 
7.5 Why is renal DNase I shutting down? 
 
Based on our data, the question “why is renal DNase I shutting down? “, becomes the most 
important to answer since factors regulating renal DNase I can be future therapeutic targets in 
lupus nephritis. So far the mechanisms leading to silencing of renal DNase I are not clear but 
are currently analyzed in our laboratory. Contemporarily we follow three lines of analyses: 
transcriptional interference with convergent encoded genes, regulation by microRNAs, or by 
DNA methylation. The initial event, accounting for DNase I shut-down may, however, 
represent a response to inflammatory signals provided by early mesangial nephritis - the 





8. Concluding remarks  
 
Our investigations illuminated important mechanisms in the pathogenesis of lupus nephritis. 
We proposed the origin of chromatin fragments in glomerular EDS and processes leading to 
their formation. We have demonstrated defects in the process of apoptotic chromatin in 
kidneys of lupus-prone mice and have renewed an interest to the dominant renal nuclease 
DNase I. Our data allow us to generate new idea to describe kidney disease progression in 
SLE. We demonstrated that lupus nephritis in lupus-prone mice is initiated through deposition 
of anti-DNA antibody-nucleosome complexes in glomerular mesangial matrixes, a process 
that largely is sub-clinical. Transformation of mild mesangial nephritis into membrano-
proliferative end-stage kidney disease is accompanied by severe proteinuria and is associated 
with a dramatically reduced renal DNase I. We have shown that shut-down of renal DNase I 
contribute to accumulation of large chromatin fragments observed as EDS in glomerular 
membranes. Deposition of such IC promotes transformation of mild mesangial nephritis into 
membrano-proliferative nephritis, induction of severe proteinuria and end-stage kidney 
disease. The observed defect in renal DNase I expression is demonstrated to be organ specific 
and shut-down of renal DNase I is shown to be selective among 7 nucleases analyzed in this 
study. Future investigation of mechanism leading to DNase I down-regulation may provide a 
new therapeutic target in lupus nephritis.               





9. References  
 
 1.  Campbell, R., Jr., G. S. Cooper, and G. S. Gilkeson. 2008. Two aspects of the clinical 
and humanistic burden of systemic lupus erythematosus: mortality risk and quality of 
life early in the course of disease. Arthritis Rheum. 59: 458-464. 
 2.  Naleway, A. L., M. E. Davis, R. T. Greenlee, D. A. Wilson, and D. J. McCarty. 2005. 
Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus 14: 862-
866. 
 3.  Peschken, C. A., and J. M. Esdaile. 2000. Systemic lupus erythematosus in North 
American Indians: a population based study. J. Rheumatol. 27: 1884-1891. 
 4.  Chakravarty, E. F., T. M. Bush, S. Manzi, A. E. Clarke, and M. M. Ward. 2007. 
Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 
2000: estimates obtained using hospitalization data. Arthritis Rheum. 56: 2092-2094. 
 5.  Uramoto, K. M., C. J. Michet, Jr., J. Thumboo, J. Sunku, W. M. O'Fallon, and S. E. 
Gabriel. 1999. Trends in the incidence and mortality of systemic lupus erythematosus, 
1950-1992. Arthritis Rheum. 42: 46-50. 
 6.  Voss, A., A. Green, and P. Junker. 1998. Systemic lupus erythematosus in Denmark: 
clinical and epidemiological characterization of a county-based cohort. Scand. J. 
Rheumatol. 27: 98-105. 
 7.  Manzi, S. 2001. Epidemiology of systemic lupus erythematosus. Am. J. Manag. Care 
7: S474-S479. 
 8.  Somers, E. C., S. L. Thomas, L. Smeeth, W. M. Schoonen, and A. J. Hall. 2007. 
Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999. 
Arthritis Rheum. 57: 612-618. 
 9.  Pons-Estel, G. J., G. S. Alarcon, L. Scofield, L. Reinlib, and G. S. Cooper. 2010. 
Understanding the epidemiology and progression of systemic lupus erythematosus. 
Semin. Arthritis Rheum. 39: 257-268. 
 10.  Pons-Estel, B. A., L. J. Catoggio, M. H. Cardiel, E. R. Soriano, S. Gentiletti, A. R. 
Villa, I. Abadi, F. Caeiro, A. Alvarellos, and D. Alarcon-Segovia. 2004. The 
GLADEL multinational Latin American prospective inception cohort of 1,214 patients 
with systemic lupus erythematosus: ethnic and disease heterogeneity among 
"Hispanics". Medicine (Baltimore) 83: 1-17. 
 11.  Alarcon, G. S., A. W. Friedman, K. V. Straaton, J. M. Moulds, J. Lisse, H. M. Bastian, 
G. McGwin, Jr., A. A. Bartolucci, J. M. Roseman, and J. D. Reveille. 1999. Systemic 
lupus erythematosus in three ethnic groups: III. A comparison of characteristics early 
in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture 
vs. Nurture. Lupus 8: 197-209. 
 12.  Block, S. R., J. B. Winfield, M. D. Lockshin, W. A. D'Angelo, M. E. Weksler, M. 
Fotino, and C. L. Christian. 1975. Proceedings: Twin studies in systemic lupus 




 13.  Deapen, D., A. Escalante, L. Weinrib, D. Horwitz, B. Bachman, P. Roy-Burman, A. 
Walker, and T. M. Mack. 1992. A revised estimate of twin concordance in systemic 
lupus erythematosus. Arthritis Rheum. 35: 311-318. 
 14.  Criswell, L. A. 2008. The genetic contribution to systemic lupus erythematosus. Bull. 
NYU. Hosp. Jt. Dis. 66: 176-183. 
 15.  Crow, M. K. 2008. Collaboration, genetic associations, and lupus erythematosus. N. 
Engl. J. Med. 358: 956-961. 
 16.  Lahita, R. G., H. L. Bradlow, H. G. Kunkel, and J. Fishman. 1981. Increased 16 alpha-
hydroxylation of estradiol in systemic lupus erythematosus. J. Clin. Endocrinol. 
Metab 53: 174-178. 
 17.  Grimaldi, C. M., J. Cleary, A. S. Dagtas, D. Moussai, and B. Diamond. 2002. Estrogen 
alters thresholds for B cell apoptosis and activation. J. Clin. Invest 109: 1625-1633. 
 18.  Peeva, E., D. Michael, J. Cleary, J. Rice, X. Chen, and B. Diamond. 2003. Prolactin 
modulates the naive B cell repertoire. J. Clin. Invest 111: 275-283. 
 19.  Minami, Y., T. Sasaki, S. Komatsu, M. Nishikori, A. Fukao, K. Yoshinaga, and S. 
Hisamichi. 1993. Female systemic lupus erythematosus in Miyagi Prefecture, Japan: a 
case-control study of dietary and reproductive factors. Tohoku J. Exp. Med. 169: 245-
252. 
 20.  Cooper, G. S., M. A. Dooley, E. L. Treadwell, E. W. St Clair, and G. S. Gilkeson. 
2002. Hormonal and reproductive risk factors for development of systemic lupus 
erythematosus: results of a population-based, case-control study. Arthritis Rheum. 46: 
1830-1839. 
 21.  Costenbader, K. H., D. Feskanich, M. J. Stampfer, and E. W. Karlson. 2007. 
Reproductive and menopausal factors and risk of systemic lupus erythematosus in 
women. Arthritis Rheum. 56: 1251-1262. 
 22.  McClain, M. T., B. D. Poole, B. F. Bruner, K. M. Kaufman, J. B. Harley, and J. A. 
James. 2006. An altered immune response to Epstein-Barr nuclear antigen 1 in 
pediatric systemic lupus erythematosus. Arthritis Rheum. 54: 360-368. 
 23.  Arbuckle, M. R., M. T. McClain, M. V. Rubertone, R. H. Scofield, G. J. Dennis, J. A. 
James, and J. B. Harley. 2003. Development of autoantibodies before the clinical onset 
of systemic lupus erythematosus. N. Engl. J. Med. 349: 1526-1533. 
 24.  Parks, C. G., G. S. Cooper, L. A. Nylander-French, W. T. Sanderson, J. M. Dement, P. 
L. Cohen, M. A. Dooley, E. L. Treadwell, E. W. St Clair, G. S. Gilkeson, J. A. 
Hoppin, and D. A. Savitz. 2002. Occupational exposure to crystalline silica and risk of 
systemic lupus erythematosus: a population-based, case-control study in the 
southeastern United States. Arthritis Rheum. 46: 1840-1850. 
 25.  Finckh, A., G. S. Cooper, L. B. Chibnik, K. H. Costenbader, J. Watts, H. Pankey, P. 
A. Fraser, and E. W. Karlson. 2006. Occupational silica and solvent exposures and 





 26.  Petri, M., and J. Allbritton. 1992. Hair product use in systemic lupus erythematosus. A 
case-control study. Arthritis Rheum. 35: 625-629. 
 27.  Cooper, G. S., M. A. Dooley, E. L. Treadwell, E. W. St Clair, and G. S. Gilkeson. 
2001. Smoking and use of hair treatments in relation to risk of developing systemic 
lupus erythematosus. J. Rheumatol. 28: 2653-2656. 
 28.  Sanchez-Guerrero, J., E. W. Karlson, G. A. Colditz, D. J. Hunter, F. E. Speizer, and 
M. H. Liang. 1996. Hair dye use and the risk of developing systemic lupus 
erythematosus. Arthritis Rheum. 39: 657-662. 
 29.  Janeway, C. A., P. Travers, M. Walport, and M. J. Shlomchik. 2005. The development 
and survival of lymphocytes. In Immunobiology, 6th ed Garland Science Publishing, 
New York and London. 241-316. 
 30.  Janeway, C. A., P. Travers, M. Walport, and M. J. Shlomchik. 2005. Basic concepts in 
immunology. In Immunobiology, 6th ed Garland Science Publishing, New York and 
London. 1-35. 
 31.  Lipsky, P. E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell 
hyperactivity. Nat. Immunol. 2: 764-766. 
 32.  Dayal, A. K., and G. M. Kammer. 1996. The T cell enigma in lupus. Arthritis Rheum. 
39: 23-33. 
 33.  Kaplan, M. J. 2004. Apoptosis in systemic lupus erythematosus. Clin. Immunol. 112: 
210-218. 
 34.  Mortensen, E. S., K. A. Fenton, and O. P. Rekvig. 2008. Lupus nephritis: the central 
role of nucleosomes revealed. Am. J. Pathol. 172: 275-283. 
 35.  Bruns, A., S. Blass, G. Hausdorf, G. R. Burmester, and F. Hiepe. 2000. Nucleosomes 
are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum. 
43: 2307-2315. 
 36.  Mohan, C., S. Adams, V. Stanik, and S. K. Datta. 1993. Nucleosome: a major 
immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 177: 
1367-1381. 
 37.  Bell, D. A., B. Morrison, and P. VandenBygaart. 1990. Immunogenic DNA-related 
factors. Nucleosomes spontaneously released from normal murine lymphoid cells 
stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes. 
J. Clin. Invest 85: 1487-1496. 
 38.  Dieker, J. W., d. van, V, and J. H. Berden. 2002. Triggers for anti-chromatin 
autoantibody production in SLE. Lupus 11: 856-864. 
 39.  Gabler, C., J. R. Kalden, and H. M. Lorenz. 2003. The putative role of apoptosis-
modified histones for the induction of autoimmunity in Systemic Lupus 




 40.  Jiang, N., C. F. Reich, III, M. Monestier, and D. S. Pisetsky. 2003. The expression of 
plasma nucleosomes in mice undergoing in vivo apoptosis. Clin. Immunol. 106: 139-
147. 
 41.  Rovere, P., M. G. Sabbadini, F. Fazzini, A. Bondanza, V. S. Zimmermann, C. Rugarli, 
and A. A. Manfredi. 2000. Remnants of suicidal cells fostering systemic 
autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis 
Rheum. 43: 1663-1672. 
 42.  Hengartner, M. O. 2000. The biochemistry of apoptosis. Nature 407: 770-776. 
 43.  Danial, N. N., and S. J. Korsmeyer. 2004. Cell death: critical control points. Cell 116: 
205-219. 
 44.  Savill, J., and V. Fadok. 2000. Corpse clearance defines the meaning of cell death. 
Nature 407: 784-788. 
 45.  Henson, P. M., D. L. Bratton, and V. A. Fadok. 2001. Apoptotic cell removal. Curr. 
Biol. 11: R795-R805. 
 46.  Voll, R. E., M. Herrmann, E. A. Roth, C. Stach, J. R. Kalden, and I. Girkontaite. 1997. 
Immunosuppressive effects of apoptotic cells. Nature 390: 350-351. 
 47.  Gershov, D., S. Kim, N. Brot, and K. B. Elkon. 2000. C-Reactive protein binds to 
apoptotic cells, protects the cells from assembly of the terminal complement 
components, and sustains an antiinflammatory innate immune response: implications 
for systemic autoimmunity. J. Exp. Med. 192: 1353-1364. 
 48.  Church, L. D., G. P. Cook, and M. F. McDermott. 2008. Primer: inflammasomes and 
interleukin 1beta in inflammatory disorders. Nat. Clin. Pract. Rheumatol. 4: 34-42. 
 49.  Li, H., A. Ambade, and F. Re. 2009. Cutting edge: Necrosis activates the NLRP3 
inflammasome. J. Immunol. 183: 1528-1532. 
 50.  Wu, X., C. Molinaro, N. Johnson, and C. A. Casiano. 2001. Secondary necrosis is a 
source of proteolytically modified forms of specific intracellular autoantigens: 
implications for systemic autoimmunity. Arthritis Rheum. 44: 2642-2652. 
 51.  Urbonaviciute, V., B. G. Furnrohr, S. Meister, L. Munoz, P. Heyder, M. F. De, M. E. 
Bianchi, C. Kirschning, H. Wagner, A. A. Manfredi, J. R. Kalden, G. Schett, P. 
Rovere-Querini, M. Herrmann, and R. E. Voll. 2008. Induction of inflammatory and 
immune responses by HMGB1-nucleosome complexes: implications for the 
pathogenesis of SLE. J. Exp. Med. 205: 3007-3018. 
 52.  Voll, R. E., V. Urbonaviciute, M. Herrmann, and J. R. Kalden. 2008. High mobility 
group box 1 in the pathogenesis of inflammatory and autoimmune diseases. Isr. Med. 
Assoc. J. 10: 26-28. 
 53.  Rosen, A., and L. Casciola-Rosen. 1999. Autoantigens as substrates for apoptotic 
proteases: implications for the pathogenesis of systemic autoimmune disease. Cell 




 54.  Kono, H., and K. L. Rock. 2008. How dying cells alert the immune system to danger. 
Nat. Rev. Immunol. 8: 279-289. 
 55.  Munoz, L. E., K. Lauber, M. Schiller, A. A. Manfredi, and M. Herrmann. 2010. The 
role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. 
Rheumatol. 6: 280-289. 
 56.  Courtney, P. A., K. Williamson, A. D. Crockard, and A. L. Bell. 1998. Apoptotic 
lymphocytes in SLE. Lupus 7: 498. 
 57.  Courtney, P. A., A. D. Crockard, K. Williamson, A. E. Irvine, R. J. Kennedy, and A. 
L. Bell. 1999. Increased apoptotic peripheral blood neutrophils in systemic lupus 
erythematosus: relations with disease activity, antibodies to double stranded DNA, and 
neutropenia. Ann. Rheum. Dis. 58: 309-314. 
 58.  Ren, Y., J. Tang, M. Y. Mok, A. W. Chan, A. Wu, and C. S. Lau. 2003. Increased 
apoptotic neutrophils and macrophages and impaired macrophage phagocytic 
clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum. 
48: 2888-2897. 
 59.  Denny, M. F., P. Chandaroy, P. D. Killen, R. Caricchio, E. E. Lewis, B. C. 
Richardson, K. D. Lee, J. Gavalchin, and M. J. Kaplan. 2006. Accelerated macrophage 
apoptosis induces autoantibody formation and organ damage in systemic lupus 
erythematosus. J. Immunol. 176: 2095-2104. 
 60.  Calvani, N., R. Caricchio, M. Tucci, E. S. Sobel, F. Silvestris, P. Tartaglia, and H. B. 
Richards. 2005. Induction of apoptosis by the hydrocarbon oil pristane: implications 
for pristane-induced lupus. J. Immunol. 175: 4777-4782. 
 61.  Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 
1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that 
mediates apoptosis. Nature 356: 314-317. 
 62.  Mysler, E., P. Bini, J. Drappa, P. Ramos, S. M. Friedman, P. H. Krammer, and K. B. 
Elkon. 1994. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J. 
Clin. Invest 93: 1029-1034. 
 63.  Suzuki, N., M. Ichino, S. Mihara, S. Kaneko, and T. Sakane. 1998. Inhibition of 
Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating 
anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis 
Rheum. 41: 344-353. 
 64.  Ratajczak, J., M. Wysoczynski, F. Hayek, A. Janowska-Wieczorek, and M. Z. 
Ratajczak. 2006. Membrane-derived microvesicles: important and underappreciated 
mediators of cell-to-cell communication. Leukemia 20: 1487-1495. 
 65.  Reich, C. F., III, and D. S. Pisetsky. 2009. The content of DNA and RNA in 
microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis. Exp. 
Cell Res. 315: 760-768. 
 66.  Beyer, C., and D. S. Pisetsky. 2010. The role of microparticles in the pathogenesis of 




 67.  Pisetsky, D. S., and P. E. Lipsky. 2010. Microparticles as autoadjuvants in the 
pathogenesis of SLE. Nat. Rev. Rheumatol. 6: 368-372. 
 68.  Yurasov, S., H. Wardemann, J. Hammersen, M. Tsuiji, E. Meffre, V. Pascual, and M. 
C. Nussenzweig. 2005. Defective B cell tolerance checkpoints in systemic lupus 
erythematosus. J. Exp. Med. 201: 703-711. 
 69.  Jacobi, A. M., J. Zhang, M. Mackay, C. Aranow, and B. Diamond. 2009. Phenotypic 
characterization of autoreactive B cells--checkpoints of B cell tolerance in patients 
with systemic lupus erythematosus. PLoS. One. 4: e5776. 
 70.  Pisetsky, D. S., J. Gauley, and A. J. Ullal. 2011. Microparticles as a source of 
extracellular DNA. Immunol. Res. 49: 227-234. 
 71.  Sellam, J., V. Proulle, A. Jungel, M. Ittah, R. C. Miceli, J. E. Gottenberg, F. Toti, J. 
Benessiano, S. Gay, J. M. Freyssinet, and X. Mariette. 2009. Increased levels of 
circulating microparticles in primary Sjogren's syndrome, systemic lupus 
erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis 
Res. Ther. 11: R156. 
 72.  Pereira, J., G. Alfaro, M. Goycoolea, T. Quiroga, M. Ocqueteau, L. Massardo, C. 
Perez, C. Saez, O. Panes, V. Matus, and D. Mezzano. 2006. Circulating platelet-
derived microparticles in systemic lupus erythematosus. Association with increased 
thrombin generation and procoagulant state. Thromb. Haemost. 95: 94-99. 
 73.  Parrish, J. Z., and D. Xue. 2006. Cuts can kill: the roles of apoptotic nucleases in cell 
death and animal development. Chromosoma 115: 89-97. 
 74.  Samejima, K., and W. C. Earnshaw. 2005. Trashing the genome: the role of nucleases 
during apoptosis. Nat. Rev. Mol. Cell Biol. 6: 677-688. 
 75.  Kawane, K., H. Fukuyama, H. Yoshida, H. Nagase, Y. Ohsawa, Y. Uchiyama, K. 
Okada, T. Iida, and S. Nagata. 2003. Impaired thymic development in mouse embryos 
deficient in apoptotic DNA degradation. Nat. Immunol. 4: 138-144. 
 76.  Oliveri, M., A. Daga, C. Cantoni, C. Lunardi, R. Millo, and A. Puccetti. 2001. DNase 
I mediates internucleosomal DNA degradation in human cells undergoing drug-
induced apoptosis. Eur. J. Immunol. 31: 743-751. 
 77.  Sakahira, H., M. Enari, and S. Nagata. 1998. Cleavage of CAD inhibitor in CAD 
activation and DNA degradation during apoptosis. Nature 391: 96-99. 
 78.  Enari, M., H. Sakahira, H. Yokoyama, K. Okawa, A. Iwamatsu, and S. Nagata. 1998. 
A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor 
ICAD. Nature 391: 43-50. 
 79.  Widlak, P., P. Li, X. Wang, and W. T. Garrard. 2000. Cleavage preferences of the 
apoptotic endonuclease DFF40 (caspase-activated DNase or nuclease) on naked DNA 




 80.  Zhang, J., X. Liu, D. C. Scherer, K. L. van, X. Wang, and M. Xu. 1998. Resistance to 
DNA fragmentation and chromatin condensation in mice lacking the DNA 
fragmentation factor 45. Proc. Natl. Acad. Sci. U. S. A 95: 12480-12485. 
 81.  McIlroy, D., M. Tanaka, H. Sakahira, H. Fukuyama, M. Suzuki, K. Yamamura, Y. 
Ohsawa, Y. Uchiyama, and S. Nagata. 2000. An auxiliary mode of apoptotic DNA 
fragmentation provided by phagocytes. Genes Dev. 14: 549-558. 
 82.  Li, L. Y., X. Luo, and X. Wang. 2001. Endonuclease G is an apoptotic DNase when 
released from mitochondria. Nature 412: 95-99. 
 83.  Arnoult, D., B. Gaume, M. Karbowski, J. C. Sharpe, F. Cecconi, and R. J. Youle. 
2003. Mitochondrial release of AIF and EndoG requires caspase activation 
downstream of Bax/Bak-mediated permeabilization. EMBO J. 22: 4385-4399. 
 84.  Widlak, P., L. Y. Li, X. Wang, and W. T. Garrard. 2001. Action of recombinant 
human apoptotic endonuclease G on naked DNA and chromatin substrates: 
cooperation with exonuclease and DNase I. J. Biol. Chem. 276: 48404-48409. 
 85.  Yin, X., E. O. Apostolov, S. V. Shah, X. Wang, K. V. Bogdanov, T. Buzder, A. G. 
Stewart, and A. G. Basnakian. 2007. Induction of renal endonuclease G by cisplatin is 
reduced in DNase I-deficient mice. J. Am. Soc. Nephrol. 18: 2544-2553. 
 86.  Zhang, J., M. Dong, L. Li, Y. Fan, P. Pathre, J. Dong, D. Lou, J. M. Wells, D. 
Olivares-Villagomez, K. L. van, X. Wang, and M. Xu. 2003. Endonuclease G is 
required for early embryogenesis and normal apoptosis in mice. Proc. Natl. Acad. Sci. 
U. S. A 100: 15782-15787. 
 87.  Irvine, R. A., N. Adachi, D. K. Shibata, G. D. Cassell, K. Yu, Z. E. Karanjawala, C. L. 
Hsieh, and M. R. Lieber. 2005. Generation and characterization of endonuclease G 
null mice. Mol. Cell Biol. 25: 294-302. 
 88.  Kawane, K., H. Fukuyama, G. Kondoh, J. Takeda, Y. Ohsawa, Y. Uchiyama, and S. 
Nagata. 2001. Requirement of DNase II for definitive erythropoiesis in the mouse fetal 
liver. Science 292: 1546-1549. 
 89.  Krieser, R. J., K. S. MacLea, D. S. Longnecker, J. L. Fields, S. Fiering, and A. 
Eastman. 2002. Deoxyribonuclease IIalpha is required during the phagocytic phase of 
apoptosis and its loss causes perinatal lethality. Cell Death. Differ. 9: 956-962. 
 90.  Nadano, D., T. Yasuda, and K. Kishi. 1993. Measurement of deoxyribonuclease I 
activity in human tissues and body fluids by a single radial enzyme-diffusion method. 
Clin. Chem. 39: 448-452. 
 91.  Mannherz, H. G., M. C. Peitsch, S. Zanotti, R. Paddenberg, and B. Polzar. 1995. A 
new function for an old enzyme: the role of DNase I in apoptosis. Curr. Top. 
Microbiol. Immunol. 198: 161-174. 
 92.  Napirei, M., S. Wulf, and H. G. Mannherz. 2004. Chromatin breakdown during 





 93.  Peitsch, M. C., B. Polzar, H. Stephan, T. Crompton, H. R. MacDonald, H. G. 
Mannherz, and J. Tschopp. 1993. Characterization of the endogenous 
deoxyribonuclease involved in nuclear DNA degradation during apoptosis 
(programmed cell death). EMBO J. 12: 371-377. 
 94.  Napirei, M., H. Karsunky, B. Zevnik, H. Stephan, H. G. Mannherz, and T. Moroy. 
2000. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 
25: 177-181. 
 95.  Apostolov, E. O., I. Soultanova, A. Savenka, O. O. Bagandov, X. Yin, A. G. Stewart, 
R. B. Walker, and A. G. Basnakian. 2009. Deoxyribonuclease I is essential for DNA 
fragmentation induced by gamma radiation in mice. Radiat. Res. 172: 481-492. 
 96.  Basnakian, A. G., E. O. Apostolov, X. Yin, M. Napirei, H. G. Mannherz, and S. V. 
Shah. 2005. Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J. Am. Soc. 
Nephrol. 16: 697-702. 
 97.  Liu, Q. Y., M. Ribecco, S. Pandey, P. R. Walker, and M. Sikorska. 1999. Apoptosis-
related functional features of the DNaseI-like family of nucleases. Ann. N. Y. Acad. 
Sci. 887: 60-76. 
 98.  Los, M., D. Neubuser, J. F. Coy, M. Mozoluk, A. Poustka, and K. Schulze-Osthoff. 
2000. Functional characterization of DNase X, a novel endonuclease expressed in 
muscle cells. Biochemistry 39: 7365-7373. 
 99.  Okamoto, M., N. Okamoto, H. Yashiro, D. Shiokawa, S. Sunaga, A. Yoshimori, S. 
Tanuma, and D. Kitamura. 2005. Involvement of DNase gamma in the resected 
double-strand DNA breaks in immunoglobulin genes. Biochem. Biophys. Res. 
Commun. 327: 76-83. 
 100.  Shiokawa, D., and S. Tanuma. 2001. Characterization of human DNase I family 
endonucleases and activation of DNase gamma during apoptosis. Biochemistry 40: 
143-152. 
 101.  Baron, W. F., C. Q. Pan, S. A. Spencer, A. M. Ryan, R. A. Lazarus, and K. P. Baker. 
1998. Cloning and characterization of an actin-resistant DNase I-like endonuclease 
secreted by macrophages. Gene 215: 291-301. 
 102.  Wilber, A., M. Lu, and M. C. Schneider. 2002. Deoxyribonuclease I-like III is an 
inducible macrophage barrier to liposomal transfection. Mol. Ther. 6: 35-42. 
 103.  Evans, C. J., and R. J. Aguilera. 2003. DNase II: genes, enzymes and function. Gene 
322: 1-15. 
 104.  Tew, M. B., R. W. Johnson, J. D. Reveille, and F. K. Tan. 2001. A molecular analysis 
of the low serum deoxyribonuclease activity in lupus patients. Arthritis Rheum. 44: 
2446-2447. 
 105.  Sallai, K., E. Nagy, B. Derfalvy, G. Muzes, and P. Gergely. 2005. Antinucleosome 
antibodies and decreased deoxyribonuclease activity in sera of patients with systemic 




 106.  Martinez-Valle, F., E. Balada, J. Ordi-Ros, S. Bujan-Rivas, A. Sellas-Fernandez, and 
M. Vilardell-Tarres. 2009. DNase 1 activity in patients with systemic lupus 
erythematosus: relationship with epidemiological, clinical, immunological and 
therapeutical features. Lupus 18: 418-423. 
 107.  Chitrabamrung, S., R. L. Rubin, and E. M. Tan. 1981. Serum deoxyribonuclease I and 
clinical activity in systemic lupus erythematosus. Rheumatol. Int. 1: 55-60. 
 108.  Macanovic, M., and P. J. Lachmann. 1997. Measurement of deoxyribonuclease I 
(DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone 
NZB/NZW mice by a new radial enzyme diffusion assay. Clin. Exp. Immunol. 108: 
220-226. 
 109.  Zykova, S. N., A. A. Tveita, and O. P. Rekvig. 2010. Renal Dnase1 enzyme activity 
and protein expression is selectively shut down in murine and human 
membranoproliferative lupus nephritis. PLoS. One. 5. 
 110.  Macanovic, M., D. Sinicropi, S. Shak, S. Baughman, S. Thiru, and P. J. Lachmann. 
1996. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid 
mice; studies with recombinant murine DNase and with dexamethasone. Clin. Exp. 
Immunol. 106: 243-252. 
 111.  Verthelyi, D., N. Dybdal, K. A. Elias, and D. M. Klinman. 1998. DNAse treatment 
does not improve the survival of lupus prone (NZB x NZW)F1 mice. Lupus 7: 223-
230. 
 112.  Davis, J. C., Jr., S. Manzi, C. Yarboro, J. Rairie, I. Mcinnes, D. Averthelyi, D. 
Sinicropi, V. G. Hale, J. Balow, H. Austin, D. T. Boumpas, and J. H. Klippel. 1999. 
Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 8: 68-
76. 
 113.  Frisoni, L., L. McPhie, S. A. Kang, M. Monestier, M. Madaio, M. Satoh, and R. 
Caricchio. 2007. Lack of chromatin and nuclear fragmentation in vivo impairs the 
production of lupus anti-nuclear antibodies. J. Immunol. 179: 7959-7966. 
 114.  Duvall, E., A. H. Wyllie, and R. G. Morris. 1985. Macrophage recognition of cells 
undergoing programmed cell death (apoptosis). Immunology 56: 351-358. 
 115.  Baumann, I., W. Kolowos, R. E. Voll, B. Manger, U. Gaipl, W. L. Neuhuber, T. 
Kirchner, J. R. Kalden, and M. Herrmann. 2002. Impaired uptake of apoptotic cells 
into tingible body macrophages in germinal centers of patients with systemic lupus 
erythematosus. Arthritis Rheum. 46: 191-201. 
 116.  Ogawa, Y., T. Yoshinaga, K. Yasuda, M. Nishikawa, and Y. Takakura. 2005. The 
uptake and degradation of DNA is impaired in macrophages and dendritic cells from 
NZB/W F(1) mice. Immunol. Lett. 101: 32-40. 
 117.  Herrmann, M., R. E. Voll, O. M. Zoller, M. Hagenhofer, B. B. Ponner, and J. R. 
Kalden. 1998. Impaired phagocytosis of apoptotic cell material by monocyte-derived 





 118.  Botto, M., C. Dell'Agnola, A. E. Bygrave, E. M. Thompson, H. T. Cook, F. Petry, M. 
Loos, P. P. Pandolfi, and M. J. Walport. 1998. Homozygous C1q deficiency causes 
glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19: 56-59. 
 119.  Hanayama, R., M. Tanaka, K. Miyasaka, K. Aozasa, M. Koike, Y. Uchiyama, and S. 
Nagata. 2004. Autoimmune disease and impaired uptake of apoptotic cells in MFG-
E8-deficient mice. Science 304: 1147-1150. 
 120.  Manderson, A. P., M. Botto, and M. J. Walport. 2004. The role of complement in the 
development of systemic lupus erythematosus. Annu. Rev. Immunol. 22: 431-456. 
 121.  Martens, H. A., M. W. Zuurman, A. H. de Lange, I. M. Nolte, G. van der Steege, G. J. 
Navis, C. G. Kallenberg, M. A. Seelen, and M. Bijl. 2009. Analysis of C1q 
polymorphisms suggests association with systemic lupus erythematosus, serum C1q 
and CH50 levels and disease severity. Ann. Rheum. Dis. 68: 715-720. 
 122.  BENACERRAF, B., M. SEBESTYEN, and N. S. COOPER. 1959. The clearance of 
antigen antibody complexes from the blood by the reticuloendothelial system. J. 
Immunol. 82: 131-137. 
 123.  Davies, K. A., K. Erlendsson, H. L. Beynon, A. M. Peters, K. Steinsson, H. 
Valdimarsson, and M. J. Walport. 1993. Splenic uptake of immune complexes in man 
is complement-dependent. J. Immunol. 151: 3866-3873. 
 124.  Skogh, T., R. Blomhoff, W. Eskild, and T. Berg. 1985. Hepatic uptake of circulating 
IgG immune complexes. Immunology 55: 585-594. 
 125.  Davies, K. A., A. M. Peters, H. L. Beynon, and M. J. Walport. 1992. Immune complex 
processing in patients with systemic lupus erythematosus. In vivo imaging and 
clearance studies. J. Clin. Invest 90: 2075-2083. 
 126.  Schifferli, J. A., Y. C. Ng, J. P. Paccaud, and M. J. Walport. 1989. The role of 
hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in 
determining abnormal immune complex clearance in humans. Clin. Exp. Immunol. 75: 
329-335. 
 127.  Madi, N., G. Steiger, J. Estreicher, and J. A. Schifferli. 1991. Immune adherence and 
clearance of hepatitis B surface Ag/Ab complexes is abnormal in patients with 
systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 85: 373-378. 
 128.  Qureshi, F., Y. Yang, S. M. Jaques, M. P. Johnson, Y. Naparstek, R. Ulmansky, and 
L. Schuger. 2000. Anti-DNA antibodies cross-reacting with laminin inhibit 
trophoblast attachment and migration: implications for recurrent pregnancy loss in 
SLE patients. Am. J. Reprod. Immunol. 44: 136-142. 
 129.  Sabbaga, J., S. R. Line, P. Potocnjak, and M. P. Madaio. 1989. A murine 
nephritogenic monoclonal anti-DNA autoantibody binds directly to mouse laminin, 
the major non-collagenous protein component of the glomerular basement membrane. 
Eur. J. Immunol. 19: 137-143. 
 130.  Deocharan, B., X. Qing, J. Lichauco, and C. Putterman. 2002. Alpha-actinin is a cross-




 131.  Mason, L. J., C. T. Ravirajan, A. Rahman, C. Putterman, and D. A. Isenberg. 2004. Is 
alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis 
Rheum. 50: 866-870. 
 132.  Berden, J. H., R. Licht, M. C. van Bruggen, and W. J. Tax. 1999. Role of nucleosomes 
for induction and glomerular binding of autoantibodies in lupus nephritis. Curr. Opin. 
Nephrol. Hypertens. 8: 299-306. 
 133.  van Bavel, C. C., K. A. Fenton, O. P. Rekvig, d. van, V, and J. H. Berden. 2008. 
Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. 
Arthritis Rheum. 58: 1892-1899. 
 134.  Clynes, R., C. Dumitru, and J. V. Ravetch. 1998. Uncoupling of immune complex 
formation and kidney damage in autoimmune glomerulonephritis. Science 279: 1052-
1054. 
 135.  Cabral, A. R., J. Cabiedes, and D. Alarcon-Segovia. 1990. Hemolytic anemia related 
to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to 
bromelain-treated human erythrocytes. J. Autoimmun. 3: 773-787. 
 136.  Alarcon-Segovia, D., and A. R. Cabral. 1994. Antiphospholipid antibodies. Where do 
they come from? Where do they go? J. Rheumatol. 21: 982-989. 
 137.  Braun, A., J. Sis, R. Max, K. Mueller, C. Fiehn, M. Zeier, and K. Andrassy. 2007. 
Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to 
other systemic autoimmune diseases. Scand. J. Rheumatol. 36: 291-298. 
 138.  Ghillani-Dalbin, P., Z. Amoura, P. Cacoub, J. L. Charuel, M. C. Diemert, J. C. Piette, 
and L. Musset. 2003. Testing for anti-nucleosome antibodies in daily practice: a 
monocentric evaluation in 1696 patients. Lupus 12: 833-837. 
 139.  Tan, E. M., A. S. Cohen, J. F. Fries, A. T. Masi, D. J. McShane, N. F. Rothfield, J. G. 
Schaller, N. Talal, and R. J. Winchester. 1982. The 1982 revised criteria for the 
classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271-1277. 
 140.  Petri, M. 2005. Review of classification criteria for systemic lupus erythematosus. 
Rheum. Dis. Clin. North Am. 31: 245-54, vi. 
 141.  Nossent, J. C., W. Bronsveld, and A. J. Swaak. 1989. Systemic lupus erythematosus. 
III. Observations on clinical renal involvement and follow up of renal function: Dutch 
experience with 110 patients studied prospectively. Ann. Rheum. Dis. 48: 810-816. 
 142.  Sidiropoulos, P. I., H. D. Kritikos, and D. T. Boumpas. 2005. Lupus nephritis flares. 
Lupus 14: 49-52. 
 143.  Baldwin, D. S., J. Lowenstein, N. F. Rothfield, G. Gallo, and R. T. McCluskey. 1970. 
The clinical course of the proliferative and membranous forms of lupus nephritis. Ann. 
Intern. Med. 73: 929-942. 
 144.  Korbet, S. M., M. M. Schwartz, J. Evans, and E. J. Lewis. 2007. Severe lupus 





 145.  Appel, G. B., G. Contreras, M. A. Dooley, E. M. Ginzler, D. Isenberg, D. Jayne, L. S. 
Li, E. Mysler, J. Sanchez-Guerrero, N. Solomons, and D. Wofsy. 2009. 
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus 
nephritis. J. Am. Soc. Nephrol. 20: 1103-1112. 
 146.  Mok, C. C. 2006. Therapeutic options for resistant lupus nephritis. Semin. Arthritis 
Rheum. 36: 71-81. 
 147.  Costenbader, K. H., D. H. Solomon, W. Winkelmayer, and M. A. Brookhart. 2008. 
Incidence of end-stage renal disease due to lupus nephritis in the US, 1995-2004. In 
Ammerican College of Rheumatology (ASR) 2008 Annual Scientific Meeting. 
 148.  Nossent, J. C., S. C. Henzen-Logmans, T. M. Vroom, V. Huysen, J. H. Berden, and A. 
J. Swaak. 1991. Relation between serological data at the time of biopsy and renal 
histology in lupus nephritis. Rheumatol. Int. 11: 77-82. 
 149.  Mittal, B., H. Rennke, and A. K. Singh. 2005. The role of kidney biopsy in the 
management of lupus nephritis. Curr. Opin. Nephrol. Hypertens. 14: 1-8. 
 150.  Hill, G. S., M. Delahousse, D. Nochy, P. Remy, F. Mignon, J. P. Mery, and J. Bariety. 
2001. Predictive power of the second renal biopsy in lupus nephritis: significance of 
macrophages. Kidney Int. 59: 304-316. 
 151.  Yoo, C. W., M. K. Kim, and H. S. Lee. 2000. Predictors of renal outcome in diffuse 
proliferative lupus nephropathy: data from repeat renal biopsy. Nephrol. Dial. 
Transplant. 15: 1604-1608. 
 152.  Cai, X., X. Yang, F. Lian, X. Lin, M. Liang, J. Li, X. Chen, L. Liang, S. Qin, and J. 
Fu. 2010. Correlation between serum anti-C1q antibody levels and renal pathological 
characteristics and prognostic significance of anti-C1q antibody in lupus nephritis. J. 
Rheumatol. 37: 759-765. 
 153.  Oates, J. C., S. Varghese, A. M. Bland, T. P. Taylor, S. E. Self, R. Stanislaus, J. S. 
Almeida, and J. M. Arthur. 2005. Prediction of urinary protein markers in lupus 
nephritis. Kidney Int. 68: 2588-2592. 
 154.  Schiffer, L., P. Kumpers, A. M. Davalos-Misslitz, M. Haubitz, H. Haller, H. J. Anders, 
T. Witte, and M. Schiffer. 2009. B-cell-attracting chemokine CXCL13 as a marker of 
disease activity and renal involvement in systemic lupus erythematosus (SLE). 
Nephrol. Dial. Transplant. 24: 3708-3712. 
 155.  Weening, J. J., V. D. D'Agati, M. M. Schwartz, S. V. Seshan, C. E. Alpers, G. B. 
Appel, J. E. Balow, J. A. Bruijn, T. Cook, F. Ferrario, A. B. Fogo, E. M. Ginzler, L. 
Hebert, G. Hill, P. Hill, J. C. Jennette, N. C. Kong, P. Lesavre, M. Lockshin, L. M. 
Looi, H. Makino, L. A. Moura, and M. Nagata. 2004. The classification of 
glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 
15: 241-250. 
 156.  Hiramatsu, N., T. Kuroiwa, H. Ikeuchi, A. Maeshima, Y. Kaneko, K. Hiromura, K. 
Ueki, and Y. Nojima. 2008. Revised classification of lupus nephritis is valuable in 
predicting renal outcome with an indication of the proportion of glomeruli affected by 




 157.  Austin, H. A., and G. G. Illei. 2005. Membranous lupus nephritis. Lupus 14: 65-71. 
 158.  Esdaile, J. M., C. Levinton, W. Federgreen, J. P. Hayslett, and M. Kashgarian. 1989. 
The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a 
study of 87 patients and review of the literature. Q. J. Med. 72: 779-833. 
 159.  Schwartz, M. M., J. S. Fennell, and E. J. Lewis. 1982. Pathologic changes in the renal 
tubule in systemic lupus erythematosus. Hum. Pathol. 13: 534-547. 
 160.  Hsieh, C., A. Chang, D. Brandt, R. Guttikonda, T. O. Utset, and M. R. Clark. 2011. 
Tubulointerstitial inflammation and scarring predict outcome in lupus nephritis. 
Arthritis Care Res. (Hoboken. ). 
 161.  Mori, Y., N. Kishimoto, H. Yamahara, Y. Kijima, A. Nose, Y. Uchiyama-Tanaka, M. 
Fukui, T. Kitamura, T. Tokoro, H. Masaki, T. Nagata, Y. Umeda, M. Nishikawa, and 
T. Iwasaka. 2005. Predominant tubulointerstitial nephritis in a patient with systemic 
lupus nephritis. Clin. Exp. Nephrol. 9: 79-84. 
 162.  Ben-Bassat, M., J. Rosenfeld, H. Joshua, B. Hazaz, and V. Gura. 1979. Lupus 
nephritis. Electron-dense and immunofluorescent deposits and their correlation with 
proteinuria and renal function. Am. J. Clin. Pathol. 72: 186-193. 
 163.  Dillard, M. G., R. L. Tillman, and C. C. Sampson. 1975. Lupus Nephritis. Correlations 
between the clinical course and presence of electron-dense deposits. Lab Invest 32: 
261-269. 
 164.  Lefkowith, J. B., and G. S. Gilkeson. 1996. Nephritogenic autoantibodies in lupus: 
current concepts and continuing controversies. Arthritis Rheum. 39: 894-903. 
 165.  Kalaaji, M., E. Mortensen, L. Jorgensen, R. Olsen, and O. P. Rekvig. 2006. 
Nephritogenic lupus antibodies recognize glomerular basement membrane-associated 
chromatin fragments released from apoptotic intraglomerular cells. Am. J. Pathol. 168: 
1779-1792. 
 166.  Kalaaji, M., K. A. Fenton, E. S. Mortensen, R. Olsen, G. Sturfelt, P. Alm, and O. P. 
Rekvig. 2007. Glomerular apoptotic nucleosomes are central target structures for 
nephritogenic antibodies in human SLE nephritis. Kidney Int. 71: 664-672. 
 167.  Rekvig, O. P., and J. C. Nossent. 2003. Anti-double-stranded DNA antibodies, 
nucleosomes, and systemic lupus erythematosus: a time for new paradigms? Arthritis 
Rheum. 48: 300-312. 
 168.  Manson, J. J., A. Ma, P. Rogers, L. J. Mason, J. H. Berden, d. van, V, D. P. D'Cruz, D. 
A. Isenberg, and A. Rahman. 2009. Relationship between anti-dsDNA, anti-
nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients 
with lupus nephritis: a prospective longitudinal study. Arthritis Res. Ther. 11: R154. 
 169.  Ravirajan, C. T., L. Rowse, J. R. MacGowan, and D. A. Isenberg. 2001. An analysis 
of clinical disease activity and nephritis-associated serum autoantibody profiles in 
patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology. 




 170.  Malide, D., I. Londono, P. Russo, and M. Bendayan. 1993. Ultrastructural localization 
of DNA in immune deposits of human lupus nephritis. Am. J. Pathol. 143: 304-311. 
 171.  van Bruggen, M. C., C. Kramers, B. Walgreen, J. D. Elema, C. G. Kallenberg, B. J. 
van den, R. J. Smeenk, K. J. Assmann, S. Muller, M. Monestier, and J. H. Berden. 
1997. Nucleosomes and histones are present in glomerular deposits in human lupus 
nephritis. Nephrol. Dial. Transplant. 12: 57-66. 
 172.  Ebling, F., and B. H. Hahn. 1980. Restricted subpopulations of DNA antibodies in 
kidneys of mice with systemic lupus. Comparison of antibodies in serum and renal 
eluates. Arthritis Rheum. 23: 392-403. 
 173.  Lambert, P. H., and F. J. Dixon. 1968. Pathogenesis of the glomerulonephritis of 
NZB/W mice. J. Exp. Med. 127: 507-522. 
 174.  Raz, E., M. Brezis, E. Rosenmann, and D. Eilat. 1989. Anti-DNA antibodies bind 
directly to renal antigens and induce kidney dysfunction in the isolated perfused rat 
kidney. J. Immunol. 142: 3076-3082. 
 175.  Vlahakos, D. V., M. H. Foster, S. Adams, M. Katz, A. A. Ucci, K. J. Barrett, S. K. 
Datta, and M. P. Madaio. 1992. Anti-DNA antibodies form immune deposits at 
distinct glomerular and vascular sites. Kidney Int. 41: 1690-1700. 
 176.  Fenton, K. A., B. Tommeras, T. N. Marion, and O. P. Rekvig. 2010. Pure anti-dsDNA 
mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c 
mice. Autoimmunity 43: 179-188. 
 177.  Desai, D. D., M. R. Krishnan, J. T. Swindle, and T. N. Marion. 1993. Antigen-specific 
induction of antibodies against native mammalian DNA in nonautoimmune mice. J. 
Immunol. 151: 1614-1626. 
 178.  Gilkeson, G. S., J. P. Grudier, D. G. Karounos, and D. S. Pisetsky. 1989. Induction of 
anti-double stranded DNA antibodies in normal mice by immunization with bacterial 
DNA. J. Immunol. 142: 1482-1486. 
 179.  Moens, U., O. M. Seternes, A. W. Hey, Y. Silsand, T. Traavik, B. Johansen, and O. P. 
Rekvig. 1995. In vivo expression of a single viral DNA-binding protein generates 
systemic lupus erythematosus-related autoimmunity to double-stranded DNA and 
histones. Proc. Natl. Acad. Sci. U. S. A 92: 12393-12397. 
 180.  Voll, R. E., E. A. Roth, I. Girkontaite, H. Fehr, M. Herrmann, H. M. Lorenz, and J. R. 
Kalden. 1997. Histone-specific Th0 and Th1 clones derived from systemic lupus 
erythematosus patients induce double-stranded DNA antibody production. Arthritis 
Rheum. 40: 2162-2171. 
 181.  Mostoslavsky, G., R. Fischel, N. Yachimovich, Y. Yarkoni, E. Rosenmann, M. 
Monestier, M. Baniyash, and D. Eilat. 2001. Lupus anti-DNA autoantibodies cross-
react with a glomerular structural protein: a case for tissue injury by molecular 




 182.  Zhao, Z., E. Weinstein, M. Tuzova, A. Davidson, P. Mundel, P. Marambio, and C. 
Putterman. 2005. Cross-reactivity of human lupus anti-DNA antibodies with alpha-
actinin and nephritogenic potential. Arthritis Rheum. 52: 522-530. 
 183.  Mageed, R. A., and D. J. Zack. 2002. Cross-reactivity and pathogenicity of anti-DNA 
autoantibodies in systemic lupus erythematosus. Lupus 11: 783-786. 
 184.  Bernstein, K. A., R. D. Valerio, and J. B. Lefkowith. 1995. Glomerular binding 
activity in MRL lpr serum consists of antibodies that bind to a DNA/histone/type IV 
collagen complex. J. Immunol. 154: 2424-2433. 
 185.  Mjelle, J. E., O. P. Rekvig, and K. A. Fenton. 2007. Nucleosomes possess a high 
affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in 
murine lupus-like nephritis. Ann. Rheum. Dis. 66: 1661-1668. 
 186.  Kalaaji, M., G. Sturfelt, J. E. Mjelle, H. Nossent, and O. P. Rekvig. 2006. Critical 
comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human 
and murine lupus nephritis. Arthritis Rheum. 54: 914-926. 
 187.  Jeruc, J., A. Vizjak, B. Rozman, and D. Ferluga. 2006. Immunohistochemical 
expression of activated caspase-3 as a marker of apoptosis in glomeruli of human 
lupus nephritis. Am. J. Kidney Dis. 48: 410-418. 
 188.  Makino, H., H. Sugiyama, Y. Yamasaki, Y. Maeshima, J. Wada, and N. Kashihara. 
2003. Glomerular cell apoptosis in human lupus nephritis. Virchows Arch. 443: 67-77. 
 189.  Wagrowska-Danilewicz, M., and M. Danilewicz. 1998. Apoptosis in lupus SLE-N IV 
and non-lupus mesangiocapillary glomerulonephritis type I MCGN. I. A comparative 
study. J. Nephrol. 11: 44-49. 
 190.  Soto, H., J. Mosquera, B. Rodriguez-Iturbe, R. C. Henriquez La, and A. Pinto. 1997. 
Apoptosis in proliferative glomerulonephritis: decreased apoptosis expression in lupus 
nephritis. Nephrol. Dial. Transplant. 12: 273-280. 
 191.  Martinez-Valle, F., E. Balada, J. Ordi-Ros, S. Bujan-Rivas, A. Sellas-Fernandez, and 
M. Vilardell-Tarres. 2010. DNase1 activity in systemic lupus erythematosus patients 
with and without nephropathy. Rheumatol. Int. 30: 1601-1604. 
 192.  Ludwig, S., H. G. Mannherz, S. Schmitt, M. Schaffer, H. Zentgraf, and M. Napirei. 
2009. Murine serum deoxyribonuclease 1 (Dnase1) activity partly originates from the 
liver. Int. J. Biochem. Cell Biol. 41: 1079-1093. 
 193.  Burny, W., P. Lebrun, J. P. Cosyns, and J. M. Saint-Remy. 1997. Treatment with 
dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA 
antibody production and reduces severity of nephritis in MRLlpr mice. Lupus 6: 4-17. 
 194.  Mortensen, E. S., and O. P. Rekvig. 2009. Nephritogenic potential of anti-DNA 
antibodies against necrotic nucleosomes. J. Am. Soc. Nephrol. 20: 696-704. 
 195.  Davidson, A., and C. Aranow. 2010. Lupus nephritis: lessons from murine models. 




 196.  Tveita, A. A., O. P. Rekvig, and S. N. Zykova. 2008. Increased glomerular matrix 
metalloproteinase activity in murine lupus nephritis. Kidney Int. 74: 1150-1158. 
 197.  Triantafyllopoulou, A., C. W. Franzke, S. V. Seshan, G. Perino, G. D. Kalliolias, M. 
Ramanujam, R. N. van, A. Davidson, and L. B. Ivashkiv. 2010. Proliferative lesions 
and metalloproteinase activity in murine lupus nephritis mediated by type I interferons 
and macrophages. Proc. Natl. Acad. Sci. U. S. A 107: 3012-3017. 
 198.  Tveita, A., O. P. Rekvig, and S. N. Zykova. 2008. Glomerular matrix 
metalloproteinases and their regulators in the pathogenesis of lupus nephritis. Arthritis 
Res. Ther. 10: 229. 
 199.  Burnet, F. M., and M. C. Holmes. 1965. The natural history of the NZB/NZW F1 
hybrid mouse: a laboratory model of systemic lupus erythematosus. Australas. Ann. 
Med. 14: 185-191. 
 200.  Huston, D. P., and A. D. Steinberg. 1979. Animal models of human systemic lupus 
erythematosus. Yale J. Biol. Med. 52: 289-305. 
 201.  Theofilopoulos, A. N., and F. J. Dixon. 1985. Murine models of systemic lupus 
erythematosus. Adv. Immunol. 37: 269-390. 
 202.  Zykova, S. N., N. Seredkina, J. Benjaminsen, and O. P. Rekvig. 2008. Reduced 
fragmentation of apoptotic chromatin is associated with nephritis in lupus-prone (NZB 
x NZW)F(1) mice. Arthritis Rheum. 58: 813-825. 
 203.  Mannik, M. 1982. Pathophysiology of circulating immune complexes. Arthritis 
Rheum. 25: 783-787. 
 204.  Couser, W. G., and D. J. Salant. 1980. In situ immune complex formation and 
glomerular injury. Kidney Int. 17: 1-13. 
 205.  Chen, M., Y. Y. Wang, M. H. Zhao, Y. K. Zhang, and H. Y. Wang. 2005. 
Autoantibodies against glomerular mesangial cells and their target antigens in lupus 
nephritis. Ren Fail. 27: 507-513. 
 206.  Seredkina, N., S. N. Zykova, and O. P. Rekvig. 2009. Progression of murine lupus 
nephritis is linked to acquired renal Dnase1 deficiency and not to up-regulated 
apoptosis. Am. J. Pathol. 175: 97-106. 
 207.  Okuda, M., K. Masaki, S. Fukatsu, Y. Hashimoto, and K. Inui. 2000. Role of 
apoptosis in cisplatin-induced toxicity in the renal epithelial cell line LLC-PK1. 
Implication of the functions of apical membranes. Biochem. Pharmacol. 59: 195-201. 
 208.  Lieberthal, W., V. Triaca, and J. Levine. 1996. Mechanisms of death induced by 
cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am. J. Physiol 
270: F700-F708. 
 209.  Basnakian, A. G., A. B. Singh, and S. V. Shah. 2002. Identification and expression of 




 210.  Napirei, M., A. Gultekin, T. Kloeckl, T. Moroy, J. Frostegard, and H. G. Mannherz. 
2006. Systemic lupus-erythematosus: deoxyribonuclease 1 in necrotic chromatin 
disposal. Int. J. Biochem. Cell Biol. 38: 297-306. 
 211.  GAVOSTO, F., F. BUFFA, and G. MARAINI. 1959. Serum deoxyribonuclease I and 
II in pathologic conditions other than pancreas diseases. Clin. Chim. Acta 4: 192-196. 
 212.  KOWLESSAR, O. D., and R. K. Mcedoy. 1956. J. Clin. Invest 35. 
 213.  Spandidos, D. A., G. Ramandanis, J. Garas, and S. D. Kottaridis. 1980. Serum 
deoxyribonucleases in patients with breast cancer. Eur. J. Cancer 16: 1615-1619. 
 214.  Scully, C., D. A. Spandidos, B. P. Ward, I. A. McGregor, and P. Boyle. 1981. Serum 
alkaline deoxyribonuclease in oral cancer and premalignant lesions. Biomedicine. 35: 
179-180. 
 215.  Lykourinas, M., C. Constantinidis, A. Spantidos, A. Manthopoulos, and C. 
Dimopoulos. 1982. The role of acid and alkaline DNases as tumour markers in cancer 
of the genitourinary tract. Urol. Res. 10: 67-70. 
 216.  Miyauchi, K., M. Ogawa, T. Shibata, K. Matsuda, T. Mori, K. Ito, N. Minamiura, and 
T. Yamamoto. 1986. Development of a radioimmunoassay for human 
deoxyribonuclease I. Clin. Chim. Acta 154: 115-123. 
 217.  Fenton, K., S. Fismen, A. Hedberg, N. Seredkina, C. Fenton, E. S. Mortensen, and O. 
P. Rekvig. 2009. Anti-dsDNA antibodies promote initiation, and acquired loss of renal 
Dnase1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. 
PLoS. One. 4: e8474. 
 218.  Fismen, S., A. Hedberg, K. A. Fenton, S. Jacobsen, E. Krarup, A. L. Kamper, O. P. 
Rekvig, and E. S. Mortensen. 2009. Circulating chromatin-anti-chromatin antibody 
complexes bind with high affinity to dermo-epidermal structures in murine and human 
lupus nephritis. Lupus 18: 597-607. 
 219.  Hedberg, A., S. Fismen, K. A. Fenton, E. S. Mortensen, and O. P. Rekvig. 2010. 
Deposition of chromatin-IgG complexes in skin of nephritic MRL-lpr/lpr mice is 
associated with increased local matrix metalloprotease activities. Exp. Dermatol. 19: 
e265-e274. 
 220.  Napirei, M., A. Ricken, D. Eulitz, H. Knoop, and H. G. Mannherz. 2004. Expression 
pattern of the deoxyribonuclease 1 gene: lessons from the Dnase1 knockout mouse. 
Biochem. J. 380: 929-937. 
 221.  Takeshita, H., K. Mogi, T. Yasuda, T. Nakajima, Y. Nakashima, S. Mori, T. Hoshino, 
and K. Kishi. 2000. Mammalian deoxyribonucleases I are classified into three types: 
pancreas, parotid, and pancreas-parotid (mixed), based on differences in their tissue 
concentrations. Biochem. Biophys. Res. Commun. 269: 481-484. 
 222.  Hepburn, A. L., I. A. Lampert, J. J. Boyle, D. Horncastle, W. F. Ng, M. Layton, T. J. 
Vyse, M. Botto, and J. C. Mason. 2007. In vivo evidence for apoptosis in the bone 






 223.  Kuhn, A., M. Herrmann, S. Kleber, M. Beckmann-Welle, K. Fehsel, A. Martin-
Villalba, P. Lehmann, T. Ruzicka, P. H. Krammer, and V. Kolb-Bachofen. 2006. 
Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus 
erythematosus after ultraviolet irradiation. Arthritis Rheum. 54: 939-950. 
 224.  Ogawa, Y., T. Yoshinaga, K. Yasuda, M. Nishikawa, and Y. Takakura. 2005. The 
uptake and degradation of DNA is impaired in macrophages and dendritic cells from 
NZB/W F(1) mice. Immunol. Lett. 101: 32-40. 
 225.  Truedsson, L., A. A. Bengtsson, and G. Sturfelt. 2007. Complement deficiencies and 
systemic lupus erythematosus. Autoimmunity 40: 560-566. 
 226.  Botto, M., and M. J. Walport. 2002. C1q, autoimmunity and apoptosis. 
Immunobiology 205: 395-406. 
 227.  Savill, J., I. Dransfield, C. Gregory, and C. Haslett. 2002. A blast from the past: 
clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2: 965-
975. 
 228.  Gardai, S. J., K. A. McPhillips, S. C. Frasch, W. J. Janssen, A. Starefeldt, J. E. 
Murphy-Ullrich, D. L. Bratton, P. A. Oldenborg, M. Michalak, and P. M. Henson. 
2005. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through 
trans-activation of LRP on the phagocyte. Cell 123: 321-334. 
 229.  Arur, S., U. E. Uche, K. Rezaul, M. Fong, V. Scranton, A. E. Cowan, W. Mohler, and 
D. K. Han. 2003. Annexin I is an endogenous ligand that mediates apoptotic cell 
engulfment. Dev. Cell 4: 587-598. 
 230.  Asano, K., M. Miwa, K. Miwa, R. Hanayama, H. Nagase, S. Nagata, and M. Tanaka. 
2004. Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces 
autoantibody production in mice. J. Exp. Med. 200: 459-467. 
 231.  Fadok, V. A., D. L. Bratton, L. Guthrie, and P. M. Henson. 2001. Differential effects 
of apoptotic versus lysed cells on macrophage production of cytokines: role of 
proteases. J. Immunol. 166: 6847-6854. 
 232.  Fismen, S., E. S. Mortensen, and O. P. Rekvig. 2011. Nuclease deficiencies promote 
end-stage lupus nephritis but not nephritogenic autoimmunity in (NZB x NZW) F1 
mice. Immunol. Cell Biol. 89: 90-99. 
 
 
 
 
 
 
 
 
 
 
Paper I 
 
 
 
 
 
 
 
 
 
Paper II 
 
 
 
 
 
 
 
 
 
Paper III 
 
 
 
 
 
 
 
 
 
Paper IV 
 
  
 
 
 
 
 
 
 
ISBN xxx-xx-xxxx-xxx-x 
